JP6891262B2 - 哺乳動物のチロシンキナーゼｒｏｒ１活性の阻害剤として有用な２−フェニルイミダゾ［４，５−ｂ］ピリジン−７−アミン誘導体 - Google Patents
哺乳動物のチロシンキナーゼｒｏｒ１活性の阻害剤として有用な２−フェニルイミダゾ［４，５−ｂ］ピリジン−７−アミン誘導体 Download PDFInfo
- Publication number
- JP6891262B2 JP6891262B2 JP2019500778A JP2019500778A JP6891262B2 JP 6891262 B2 JP6891262 B2 JP 6891262B2 JP 2019500778 A JP2019500778 A JP 2019500778A JP 2019500778 A JP2019500778 A JP 2019500778A JP 6891262 B2 JP6891262 B2 JP 6891262B2
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- imidazole
- pyridine
- amine
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 title description 43
- 230000000694 effects Effects 0.000 title description 13
- 239000003112 inhibitor Substances 0.000 title description 5
- ZCUJYXPAKHMBAZ-UHFFFAOYSA-N 2-phenyl-1h-imidazole Chemical compound C1=CNC(C=2C=CC=CC=2)=N1 ZCUJYXPAKHMBAZ-UHFFFAOYSA-N 0.000 title description 3
- -1 6-Bromo-2- [4- (4-methylpiperazin-1-yl) phenyl] -N- (1-methylpiperidin-4-yl) -3H-imidazole Chemical compound 0.000 claims description 474
- 150000001875 compounds Chemical class 0.000 claims description 237
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 191
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 117
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 112
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 105
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 94
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 93
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 51
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 50
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 41
- 150000003839 salts Chemical class 0.000 claims description 39
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 37
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 33
- 125000005842 heteroatom Chemical group 0.000 claims description 33
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 32
- 125000002947 alkylene group Chemical group 0.000 claims description 30
- 125000004429 atom Chemical group 0.000 claims description 28
- 208000035475 disorder Diseases 0.000 claims description 24
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 23
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 claims description 23
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 20
- 229910052794 bromium Inorganic materials 0.000 claims description 17
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 16
- 229910052801 chlorine Inorganic materials 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 11
- 208000023275 Autoimmune disease Diseases 0.000 claims description 11
- 230000003463 hyperproliferative effect Effects 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N methyl cyanide Natural products CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 10
- 239000000654 additive Substances 0.000 claims description 8
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 5
- 230000000996 additive effect Effects 0.000 claims description 5
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 4
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 79
- KZKRRZFCAYOXQE-UHFFFAOYSA-N 1$l^{2}-azinane Chemical group C1CC[N]CC1 KZKRRZFCAYOXQE-UHFFFAOYSA-N 0.000 claims 18
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims 11
- JLAKCHGEEBPDQI-UHFFFAOYSA-N 4-(4-fluorobenzyl)piperidine Chemical compound C1=CC(F)=CC=C1CC1CCNCC1 JLAKCHGEEBPDQI-UHFFFAOYSA-N 0.000 claims 6
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 4
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims 4
- YRGTWBPPKALYNE-UHFFFAOYSA-N 6-chloro-N-[1-[[4-(dimethylamino)phenyl]methyl]piperidin-4-yl]-2-[4-[4-(2-methoxyethyl)piperazin-1-yl]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound ClC=1C(=C2C(=NC=1)NC(=N2)C1=CC=C(C=C1)N1CCN(CC1)CCOC)NC1CCN(CC1)CC1=CC=C(C=C1)N(C)C YRGTWBPPKALYNE-UHFFFAOYSA-N 0.000 claims 2
- 229960001867 guaiacol Drugs 0.000 claims 2
- KJCIMSSFGUGTGA-UHFFFAOYSA-N 1-methylpiperazin-2-one Chemical compound CN1CCNCC1=O KJCIMSSFGUGTGA-UHFFFAOYSA-N 0.000 claims 1
- CRNQLRKTYIIEDH-UHFFFAOYSA-N 2-[4-[4-[6-chloro-7-[[1-[(1,3,5-trimethylpyrazol-4-yl)methyl]piperidin-4-yl]amino]-1H-imidazo[4,5-b]pyridin-2-yl]phenyl]piperazin-1-yl]ethanol Chemical compound ClC=1C(=C2C(=NC=1)NC(=N2)C1=CC=C(C=C1)N1CCN(CC1)CCO)NC1CCN(CC1)CC=1C(=NN(C=1C)C)C CRNQLRKTYIIEDH-UHFFFAOYSA-N 0.000 claims 1
- PJCOQQLLFPOOFJ-UHFFFAOYSA-N 4-[4-[6-chloro-7-[[1-[(4-methoxyphenyl)methyl]piperidin-4-yl]amino]-1H-imidazo[4,5-b]pyridin-2-yl]phenyl]-1-(2-methoxyethyl)piperazin-2-one Chemical compound COCCN1CCN(CC1=O)c1ccc(cc1)-c1nc2ncc(Cl)c(NC3CCN(Cc4ccc(OC)cc4)CC3)c2[nH]1 PJCOQQLLFPOOFJ-UHFFFAOYSA-N 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- OHOIJCWXVDMYRE-UHFFFAOYSA-N 6-bromo-2-[4-[4-(2-methoxyethyl)piperazin-1-yl]phenyl]-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound BrC=1C(=C2C(=NC=1)NC(=N2)C1=CC=C(C=C1)N1CCN(CC1)CCOC)NC1CC(N(C(C1)(C)C)C)(C)C OHOIJCWXVDMYRE-UHFFFAOYSA-N 0.000 claims 1
- TUXNALRLVXLNSS-UHFFFAOYSA-N 6-bromo-2-[4-[4-(3-methoxypropyl)piperazin-1-yl]phenyl]-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound BrC=1C(=C2C(=NC=1)NC(=N2)C1=CC=C(C=C1)N1CCN(CC1)CCCOC)NC1CC(N(C(C1)(C)C)C)(C)C TUXNALRLVXLNSS-UHFFFAOYSA-N 0.000 claims 1
- QUUKEKMXFARDHG-UHFFFAOYSA-N 6-bromo-2-[4-[4-[(3,5-dimethyl-1,2-oxazol-4-yl)methyl]piperazin-1-yl]phenyl]-N-(1-methylpiperidin-4-yl)-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound BrC=1C(=C2C(=NC=1)NC(=N2)C1=CC=C(C=C1)N1CCN(CC1)CC=1C(=NOC=1C)C)NC1CCN(CC1)C QUUKEKMXFARDHG-UHFFFAOYSA-N 0.000 claims 1
- DEIPRSRSZCRSOM-UHFFFAOYSA-N 6-bromo-N-(1-methylpiperidin-4-yl)-2-[4-[2-methyl-4-(1,3-thiazol-2-ylmethyl)piperazin-1-yl]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound BrC=1C(=C2C(=NC=1)NC(=N2)C1=CC=C(C=C1)N1C(CN(CC1)CC=1SC=CN=1)C)NC1CCN(CC1)C DEIPRSRSZCRSOM-UHFFFAOYSA-N 0.000 claims 1
- HDQUWJRQJWHCHD-UHFFFAOYSA-N 6-bromo-N-(1-methylpiperidin-4-yl)-2-[4-[3-methyl-4-(1,3-thiazol-2-ylmethyl)piperazin-1-yl]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound BrC=1C(=C2C(=NC=1)NC(=N2)C1=CC=C(C=C1)N1CC(N(CC1)CC=1SC=CN=1)C)NC1CCN(CC1)C HDQUWJRQJWHCHD-UHFFFAOYSA-N 0.000 claims 1
- WNRDZKAMANTMRY-SFHVURJKSA-N 6-bromo-N-[(3S)-1-methylpyrrolidin-3-yl]-2-[4-[4-(1,3-thiazol-2-ylmethyl)piperazin-1-yl]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound BrC=1C(=C2C(=NC=1)NC(=N2)C1=CC=C(C=C1)N1CCN(CC1)CC=1SC=CN=1)N[C@@H]1CN(CC1)C WNRDZKAMANTMRY-SFHVURJKSA-N 0.000 claims 1
- WLQHURZKKFEFGI-UHFFFAOYSA-N 6-bromo-N-[1-(cyclopropylmethyl)piperidin-4-yl]-2-[2-fluoro-4-[4-(2-methoxyethyl)piperazin-1-yl]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound BrC=1C(=C2C(=NC=1)NC(=N2)C1=C(C=C(C=C1)N1CCN(CC1)CCOC)F)NC1CCN(CC1)CC1CC1 WLQHURZKKFEFGI-UHFFFAOYSA-N 0.000 claims 1
- AYRZKXFCDLHVGY-UHFFFAOYSA-N 6-bromo-N-[1-(cyclopropylmethyl)piperidin-4-yl]-2-[3-fluoro-4-[4-(2-methoxyethyl)piperazin-1-yl]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound BrC=1C(=C2C(=NC=1)NC(=N2)C1=CC(=C(C=C1)N1CCN(CC1)CCOC)F)NC1CCN(CC1)CC1CC1 AYRZKXFCDLHVGY-UHFFFAOYSA-N 0.000 claims 1
- AYXPDJJSEQFNGL-UHFFFAOYSA-N 6-bromo-N-[1-(cyclopropylmethyl)piperidin-4-yl]-2-[3-methoxy-4-[4-(2-methoxyethyl)piperazin-1-yl]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound BrC=1C(=C2C(=NC=1)NC(=N2)C1=CC(=C(C=C1)N1CCN(CC1)CCOC)OC)NC1CCN(CC1)CC1CC1 AYXPDJJSEQFNGL-UHFFFAOYSA-N 0.000 claims 1
- XPCNRBGALRRKAX-UHFFFAOYSA-N 6-bromo-N-[1-(cyclopropylmethyl)piperidin-4-yl]-2-[4-[4-(1,3-thiazol-2-ylmethyl)piperazin-1-yl]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound BrC=1C(=C2C(=NC=1)NC(=N2)C1=CC=C(C=C1)N1CCN(CC1)CC=1SC=CN=1)NC1CCN(CC1)CC1CC1 XPCNRBGALRRKAX-UHFFFAOYSA-N 0.000 claims 1
- XAGMWSTUPRQUOV-UHFFFAOYSA-N 6-bromo-N-[1-(cyclopropylmethyl)piperidin-4-yl]-2-[4-[4-[2-[(2-methylpyrazol-3-yl)amino]ethyl]piperazin-1-yl]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound BrC=1C(=C2C(=NC=1)NC(=N2)C1=CC=C(C=C1)N1CCN(CC1)CCNC1=CC=NN1C)NC1CCN(CC1)CC1CC1 XAGMWSTUPRQUOV-UHFFFAOYSA-N 0.000 claims 1
- QCLYKYCDAKNRBP-UHFFFAOYSA-N 6-chloro-2-(4-morpholin-4-ylphenyl)-N-[1-[(1,3,5-trimethylpyrazol-4-yl)methyl]piperidin-4-yl]-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound ClC=1C(=C2C(=NC=1)NC(=N2)C1=CC=C(C=C1)N1CCOCC1)NC1CCN(CC1)CC=1C(=NN(C=1C)C)C QCLYKYCDAKNRBP-UHFFFAOYSA-N 0.000 claims 1
- BXFYXRCOVANGBE-UHFFFAOYSA-N 6-chloro-2-[2-fluoro-4-[4-(2-methoxyethyl)piperazin-1-yl]phenyl]-N-(1-propan-2-ylpiperidin-4-yl)-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound ClC=1C(=C2C(=NC=1)NC(=N2)C1=C(C=C(C=C1)N1CCN(CC1)CCOC)F)NC1CCN(CC1)C(C)C BXFYXRCOVANGBE-UHFFFAOYSA-N 0.000 claims 1
- QGJYCEGNRNUTPV-UHFFFAOYSA-N 6-chloro-2-[3-fluoro-4-[4-(2-methoxyethyl)piperazin-1-yl]phenyl]-N-(1-propan-2-ylpiperidin-4-yl)-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound ClC=1C(=C2C(=NC=1)NC(=N2)C1=CC(=C(C=C1)N1CCN(CC1)CCOC)F)NC1CCN(CC1)C(C)C QGJYCEGNRNUTPV-UHFFFAOYSA-N 0.000 claims 1
- FOPXRLQWVIFZFN-UHFFFAOYSA-N 6-chloro-2-[3-methoxy-4-[4-(2-methoxyethyl)piperazin-1-yl]phenyl]-N-(1-propan-2-ylpiperidin-4-yl)-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound ClC=1C(=C2C(=NC=1)NC(=N2)C1=CC(=C(C=C1)N1CCN(CC1)CCOC)OC)NC1CCN(CC1)C(C)C FOPXRLQWVIFZFN-UHFFFAOYSA-N 0.000 claims 1
- JYQQOORRDKFAQU-DEOSSOPVSA-N 6-chloro-2-[4-[4-(2-methoxyethyl)piperazin-1-yl]phenyl]-N-[(3S)-1-[(4-methoxyphenyl)methyl]pyrrolidin-3-yl]-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound ClC=1C(=C2C(=NC=1)NC(=N2)C1=CC=C(C=C1)N1CCN(CC1)CCOC)N[C@@H]1CN(CC1)CC1=CC=C(C=C1)OC JYQQOORRDKFAQU-DEOSSOPVSA-N 0.000 claims 1
- STJOEBXLGDGKAP-UHFFFAOYSA-N 6-chloro-2-[4-[4-(2-propan-2-yloxyethyl)piperazin-1-yl]phenyl]-N-(1-propan-2-ylpiperidin-4-yl)-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound ClC=1C(=C2C(=NC=1)NC(=N2)C1=CC=C(C=C1)N1CCN(CC1)CCOC(C)C)NC1CCN(CC1)C(C)C STJOEBXLGDGKAP-UHFFFAOYSA-N 0.000 claims 1
- PCNPZDABLPLKIT-UHFFFAOYSA-N 6-chloro-2-[4-[4-(3-methoxypropyl)piperazin-1-yl]phenyl]-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound ClC=1C(=C2C(=NC=1)NC(=N2)C1=CC=C(C=C1)N1CCN(CC1)CCCOC)NC1CC(N(C(C1)(C)C)C)(C)C PCNPZDABLPLKIT-UHFFFAOYSA-N 0.000 claims 1
- DNJVCLXOWCKKKD-UHFFFAOYSA-N 6-chloro-2-[4-[4-(4-methoxybutyl)piperazin-1-yl]phenyl]-N-[1-[(4-methoxyphenyl)methyl]piperidin-4-yl]-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound ClC=1C(=C2C(=NC=1)NC(=N2)C1=CC=C(C=C1)N1CCN(CC1)CCCCOC)NC1CCN(CC1)CC1=CC=C(C=C1)OC DNJVCLXOWCKKKD-UHFFFAOYSA-N 0.000 claims 1
- WBNODXGGGWDMAM-UHFFFAOYSA-N 6-chloro-2-[4-[4-[(3,5-dimethyl-1,2-oxazol-4-yl)methyl]piperazin-1-yl]phenyl]-N-(1-methylpiperidin-4-yl)-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound ClC=1C(=C2C(=NC=1)NC(=N2)C1=CC=C(C=C1)N1CCN(CC1)CC=1C(=NOC=1C)C)NC1CCN(CC1)C WBNODXGGGWDMAM-UHFFFAOYSA-N 0.000 claims 1
- LQHFHJJDBWROAT-UHFFFAOYSA-N 6-chloro-2-[4-[4-[(6-methylpyridin-3-yl)methyl]piperazin-1-yl]phenyl]-N-(1-propan-2-ylpiperidin-4-yl)-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound ClC=1C(=C2C(=NC=1)NC(=N2)C1=CC=C(C=C1)N1CCN(CC1)CC=1C=NC(=CC=1)C)NC1CCN(CC1)C(C)C LQHFHJJDBWROAT-UHFFFAOYSA-N 0.000 claims 1
- IPXMTQJRYMJGMO-FQEVSTJZSA-N 6-chloro-2-[4-[4-[2-(2-methoxyethoxy)ethyl]piperazin-1-yl]phenyl]-N-[(3S)-1-methylpyrrolidin-3-yl]-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound ClC=1C(=C2C(=NC=1)NC(=N2)C1=CC=C(C=C1)N1CCN(CC1)CCOCCOC)N[C@@H]1CN(CC1)C IPXMTQJRYMJGMO-FQEVSTJZSA-N 0.000 claims 1
- RNBHSRVYLXYXRD-UHFFFAOYSA-N 6-chloro-2-[4-[4-[2-[(2-methylpyrazol-3-yl)amino]ethyl]piperazin-1-yl]phenyl]-N-(1-propan-2-ylpiperidin-4-yl)-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound ClC=1C(=C2C(=NC=1)NC(=N2)C1=CC=C(C=C1)N1CCN(CC1)CCNC1=CC=NN1C)NC1CCN(CC1)C(C)C RNBHSRVYLXYXRD-UHFFFAOYSA-N 0.000 claims 1
- NQPWSWPGABSWMS-UHFFFAOYSA-N 6-chloro-N-(1-ethylpiperidin-4-yl)-2-[4-[3-methyl-4-(1,3-thiazol-2-ylmethyl)piperazin-1-yl]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound ClC=1C(=C2C(=NC=1)NC(=N2)C1=CC=C(C=C1)N1CC(N(CC1)CC=1SC=CN=1)C)NC1CCN(CC1)CC NQPWSWPGABSWMS-UHFFFAOYSA-N 0.000 claims 1
- BAVQRSQJJOSUTI-UHFFFAOYSA-N 6-chloro-N-(1-methylpiperidin-4-yl)-2-[4-(4-methylsulfonylpiperazin-1-yl)phenyl]-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound ClC=1C(=C2C(=NC=1)NC(=N2)C1=CC=C(C=C1)N1CCN(CC1)S(=O)(=O)C)NC1CCN(CC1)C BAVQRSQJJOSUTI-UHFFFAOYSA-N 0.000 claims 1
- OSXANEMXTYCZMN-UHFFFAOYSA-N 6-chloro-N-(1-methylpiperidin-4-yl)-2-[4-[2-methyl-4-(1,3-thiazol-2-ylmethyl)piperazin-1-yl]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound ClC=1C(=C2C(=NC=1)NC(=N2)C1=CC=C(C=C1)N1C(CN(CC1)CC=1SC=CN=1)C)NC1CCN(CC1)C OSXANEMXTYCZMN-UHFFFAOYSA-N 0.000 claims 1
- AQXLRBHVMWPVJO-UHFFFAOYSA-N 6-chloro-N-(1-methylpiperidin-4-yl)-2-[4-[3-methyl-4-(1,3-thiazol-2-ylmethyl)piperazin-1-yl]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound ClC=1C(=C2C(=NC=1)NC(=N2)C1=CC=C(C=C1)N1CC(N(CC1)CC=1SC=CN=1)C)NC1CCN(CC1)C AQXLRBHVMWPVJO-UHFFFAOYSA-N 0.000 claims 1
- ZMJJHVNFLIVGNR-UHFFFAOYSA-N 6-chloro-N-(1-methylpiperidin-4-yl)-2-[4-[4-(pyridin-4-ylmethyl)piperazin-1-yl]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound ClC=1C(=C2C(=NC=1)NC(=N2)C1=CC=C(C=C1)N1CCN(CC1)CC1=CC=NC=C1)NC1CCN(CC1)C ZMJJHVNFLIVGNR-UHFFFAOYSA-N 0.000 claims 1
- GYRLUEPSIIGCES-UHFFFAOYSA-N 6-chloro-N-(1-methylpiperidin-4-yl)-2-[4-[4-[(5-methylpyridin-2-yl)methyl]piperazin-1-yl]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound ClC=1C(=C2C(=NC=1)NC(=N2)C1=CC=C(C=C1)N1CCN(CC1)CC1=NC=C(C=C1)C)NC1CCN(CC1)C GYRLUEPSIIGCES-UHFFFAOYSA-N 0.000 claims 1
- JUIUZXYEDLTXSM-UHFFFAOYSA-N 6-chloro-N-[1-(cyclopropylmethyl)piperidin-4-yl]-2-[2-fluoro-4-[4-(2-methoxyethyl)piperazin-1-yl]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound ClC=1C(=C2C(=NC=1)NC(=N2)C1=C(C=C(C=C1)N1CCN(CC1)CCOC)F)NC1CCN(CC1)CC1CC1 JUIUZXYEDLTXSM-UHFFFAOYSA-N 0.000 claims 1
- DUJWQDHTERYLLH-UHFFFAOYSA-N 6-chloro-N-[1-(cyclopropylmethyl)piperidin-4-yl]-2-[3-fluoro-4-[4-(2-methoxyethyl)piperazin-1-yl]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound ClC=1C(=C2C(=NC=1)NC(=N2)C1=CC(=C(C=C1)N1CCN(CC1)CCOC)F)NC1CCN(CC1)CC1CC1 DUJWQDHTERYLLH-UHFFFAOYSA-N 0.000 claims 1
- KIQALQOVNFJPGW-UHFFFAOYSA-N 6-chloro-N-[1-(cyclopropylmethyl)piperidin-4-yl]-2-[3-methoxy-4-[4-(2-methoxyethyl)piperazin-1-yl]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound ClC=1C(=C2C(=NC=1)NC(=N2)C1=CC(=C(C=C1)N1CCN(CC1)CCOC)OC)NC1CCN(CC1)CC1CC1 KIQALQOVNFJPGW-UHFFFAOYSA-N 0.000 claims 1
- IXLRJELUWODTRV-UHFFFAOYSA-N 6-chloro-N-[1-(cyclopropylmethyl)piperidin-4-yl]-2-[4-[4-(1,3-thiazol-2-ylmethyl)piperazin-1-yl]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound ClC=1C(=C2C(=NC=1)NC(=N2)C1=CC=C(C=C1)N1CCN(CC1)CC=1SC=CN=1)NC1CCN(CC1)CC1CC1 IXLRJELUWODTRV-UHFFFAOYSA-N 0.000 claims 1
- FHLUQGZMQTZMTK-UHFFFAOYSA-N 6-chloro-N-[1-(cyclopropylmethyl)piperidin-4-yl]-2-[4-[4-[2-[(2-methylpyrazol-3-yl)amino]ethyl]piperazin-1-yl]phenyl]-1H-imidazo[4,5-b]pyridin-7-amine Chemical compound ClC=1C(=C2C(=NC=1)NC(=N2)C1=CC=C(C=C1)N1CCN(CC1)CCNC1=CC=NN1C)NC1CCN(CC1)CC1CC1 FHLUQGZMQTZMTK-UHFFFAOYSA-N 0.000 claims 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 239000000543 intermediate Substances 0.000 description 298
- 238000005481 NMR spectroscopy Methods 0.000 description 217
- 239000000047 product Substances 0.000 description 140
- 238000000034 method Methods 0.000 description 127
- 125000000217 alkyl group Chemical group 0.000 description 45
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 44
- 239000000203 mixture Substances 0.000 description 44
- 206010028980 Neoplasm Diseases 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 36
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 description 35
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 description 33
- 239000007787 solid Substances 0.000 description 31
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 28
- 201000010099 disease Diseases 0.000 description 26
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 24
- 235000002639 sodium chloride Nutrition 0.000 description 22
- 125000001072 heteroaryl group Chemical group 0.000 description 21
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 20
- 230000014509 gene expression Effects 0.000 description 20
- KYVDKOZOAOAFDC-UHFFFAOYSA-N 4,5-dichloro-3-nitropyridin-2-amine Chemical compound NC1=NC=C(Cl)C(Cl)=C1[N+]([O-])=O KYVDKOZOAOAFDC-UHFFFAOYSA-N 0.000 description 19
- 239000012074 organic phase Substances 0.000 description 19
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 18
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 17
- 239000012267 brine Substances 0.000 description 17
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 17
- 239000011734 sodium Substances 0.000 description 17
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 17
- 201000011510 cancer Diseases 0.000 description 16
- 239000000460 chlorine Substances 0.000 description 16
- 208000011580 syndromic disease Diseases 0.000 description 16
- 235000019439 ethyl acetate Nutrition 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- MMYKTRPLXXWLBC-UHFFFAOYSA-N 1-bromo-2-ethoxyethane Chemical compound CCOCCBr MMYKTRPLXXWLBC-UHFFFAOYSA-N 0.000 description 14
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 14
- 125000000753 cycloalkyl group Chemical group 0.000 description 14
- 229910052760 oxygen Inorganic materials 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 14
- BMEMBBFDTYHTLH-UHFFFAOYSA-N 1-(2-methoxyethyl)piperazine Chemical compound COCCN1CCNCC1 BMEMBBFDTYHTLH-UHFFFAOYSA-N 0.000 description 13
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 13
- 230000002503 metabolic effect Effects 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- 208000008589 Obesity Diseases 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000003818 flash chromatography Methods 0.000 description 12
- 235000020824 obesity Nutrition 0.000 description 12
- 239000000377 silicon dioxide Substances 0.000 description 12
- 229910052717 sulfur Inorganic materials 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- BLGCPXIDEMLKMS-UHFFFAOYSA-N 5-bromo-4-chloro-3-nitropyridin-2-amine Chemical compound NC1=NC=C(Br)C(Cl)=C1[N+]([O-])=O BLGCPXIDEMLKMS-UHFFFAOYSA-N 0.000 description 11
- 239000012043 crude product Substances 0.000 description 11
- 230000003211 malignant effect Effects 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 9
- 0 CC(C)C(N(C)*)=O Chemical compound CC(C)C(N(C)*)=O 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 9
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 9
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 8
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 206010039710 Scleroderma Diseases 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 206010047115 Vasculitis Diseases 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000012230 colorless oil Substances 0.000 description 6
- 150000002367 halogens Chemical group 0.000 description 6
- 230000004968 inflammatory condition Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 5
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000001363 autoimmune Effects 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 230000002490 cerebral effect Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- JDACBLXRPFJSHT-UHFFFAOYSA-N 1-[(4-methoxyphenyl)methyl]piperidin-4-amine Chemical compound C1=CC(OC)=CC=C1CN1CCC(N)CC1 JDACBLXRPFJSHT-UHFFFAOYSA-N 0.000 description 4
- CEVMYGZHEJSOHZ-UHFFFAOYSA-N 1-bromo-3-methoxypropane Chemical group COCCCBr CEVMYGZHEJSOHZ-UHFFFAOYSA-N 0.000 description 4
- JJKWHOSQTYYFAE-UHFFFAOYSA-N 2-methoxyacetyl chloride Chemical compound COCC(Cl)=O JJKWHOSQTYYFAE-UHFFFAOYSA-N 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 4
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 4
- 239000005977 Ethylene Substances 0.000 description 4
- 206010018338 Glioma Diseases 0.000 description 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 4
- 102000038030 PI3Ks Human genes 0.000 description 4
- 108091007960 PI3Ks Proteins 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000001130 astrocyte Anatomy 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000002308 embryonic cell Anatomy 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- RFIOZSIHFNEKFF-UHFFFAOYSA-N piperazine-1-carboxylic acid Chemical compound OC(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-N 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- ZZYXNRREDYWPLN-UHFFFAOYSA-N pyridine-2,3-diamine Chemical compound NC1=CC=CN=C1N ZZYXNRREDYWPLN-UHFFFAOYSA-N 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000012258 stirred mixture Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- FMLPQHJYUZTHQS-UHFFFAOYSA-N tert-butyl 3-methylpiperazine-1-carboxylate Chemical compound CC1CN(C(=O)OC(C)(C)C)CCN1 FMLPQHJYUZTHQS-UHFFFAOYSA-N 0.000 description 4
- CKXZPVPIDOJLLM-UHFFFAOYSA-N tert-butyl n-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNCC1 CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 4
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 3
- SIKNYOSYSBEMJG-UHFFFAOYSA-N 1-(cyclopropylmethyl)piperidin-4-amine Chemical compound C1CC(N)CCN1CC1CC1 SIKNYOSYSBEMJG-UHFFFAOYSA-N 0.000 description 3
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 3
- JPHKMYXKNKLNDF-UHFFFAOYSA-N 3,4-difluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1F JPHKMYXKNKLNDF-UHFFFAOYSA-N 0.000 description 3
- OIVQJNFBHWSVEX-UHFFFAOYSA-N 3-(4-aminopiperidin-1-yl)propanenitrile Chemical compound NC1CCN(CCC#N)CC1 OIVQJNFBHWSVEX-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 208000007465 Giant cell arteritis Diseases 0.000 description 3
- 208000032612 Glial tumor Diseases 0.000 description 3
- 208000003456 Juvenile Arthritis Diseases 0.000 description 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000003445 Mouth Neoplasms Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 3
- SYKNUAWMBRIEKB-UHFFFAOYSA-N [Cl].[Br] Chemical compound [Cl].[Br] SYKNUAWMBRIEKB-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000013058 crude material Substances 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 201000001981 dermatomyositis Diseases 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 3
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 3
- BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical compound NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- DATRVIMZZZVHMP-UHFFFAOYSA-N tert-butyl 2-methylpiperazine-1-carboxylate Chemical compound CC1CNCCN1C(=O)OC(C)(C)C DATRVIMZZZVHMP-UHFFFAOYSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000000115 thoracic cavity Anatomy 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- XCAHYEUISIUALY-NSHDSACASA-N (3s)-1-[(4-methoxyphenyl)methyl]pyrrolidin-3-amine Chemical compound C1=CC(OC)=CC=C1CN1C[C@@H](N)CC1 XCAHYEUISIUALY-NSHDSACASA-N 0.000 description 2
- UNHOPMIDKWXFMF-YFKPBYRVSA-N (3s)-1-methylpyrrolidin-3-amine Chemical compound CN1CC[C@H](N)C1 UNHOPMIDKWXFMF-YFKPBYRVSA-N 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 description 2
- CGXOAAMIQPDTPE-UHFFFAOYSA-N 1,2,2,6,6-pentamethylpiperidin-4-amine Chemical compound CN1C(C)(C)CC(N)CC1(C)C CGXOAAMIQPDTPE-UHFFFAOYSA-N 0.000 description 2
- TZXBALTUSCDXLU-UHFFFAOYSA-N 1-(2,3-dihydro-1-benzofuran-5-ylmethyl)piperidin-4-amine Chemical compound C1CC(N)CCN1CC1=CC=C(OCC2)C2=C1 TZXBALTUSCDXLU-UHFFFAOYSA-N 0.000 description 2
- NQQVCDIEQDMPOD-UHFFFAOYSA-N 1-(thiophen-2-ylmethyl)piperidin-4-amine Chemical compound C1CC(N)CCN1CC1=CC=CS1 NQQVCDIEQDMPOD-UHFFFAOYSA-N 0.000 description 2
- NTNFMOPKOCZICX-UHFFFAOYSA-N 1-(thiophen-3-ylmethyl)piperidin-4-amine Chemical compound C1CC(N)CCN1CC1=CSC=C1 NTNFMOPKOCZICX-UHFFFAOYSA-N 0.000 description 2
- CZEBDZMBUKUETA-UHFFFAOYSA-N 1-[[4-(dimethylamino)phenyl]methyl]piperidin-4-amine Chemical compound C1=CC(N(C)C)=CC=C1CN1CCC(N)CC1 CZEBDZMBUKUETA-UHFFFAOYSA-N 0.000 description 2
- UIJWNLIBMHVUOS-UHFFFAOYSA-N 1-ethylpiperidin-4-amine;dihydrochloride Chemical compound Cl.Cl.CCN1CCC(N)CC1 UIJWNLIBMHVUOS-UHFFFAOYSA-N 0.000 description 2
- ALOCUZOKRULSAA-UHFFFAOYSA-N 1-methylpiperidin-4-amine Chemical compound CN1CCC(N)CC1 ALOCUZOKRULSAA-UHFFFAOYSA-N 0.000 description 2
- VTDIWMPYBAVEDY-UHFFFAOYSA-N 1-propylpiperidine Chemical compound CCCN1CCCCC1 VTDIWMPYBAVEDY-UHFFFAOYSA-N 0.000 description 2
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 2
- IFFLKGMDBKQMAH-UHFFFAOYSA-N 2,4-diaminopyridine Chemical compound NC1=CC=NC(N)=C1 IFFLKGMDBKQMAH-UHFFFAOYSA-N 0.000 description 2
- PKZJLOCLABXVMC-UHFFFAOYSA-N 2-Methoxybenzaldehyde Chemical compound COC1=CC=CC=C1C=O PKZJLOCLABXVMC-UHFFFAOYSA-N 0.000 description 2
- XOJHPVYUYLWBSO-UHFFFAOYSA-N 3-[4-(4-formylphenyl)piperazin-1-yl]propanenitrile Chemical compound C1=CC(C=O)=CC=C1N1CCN(CCC#N)CC1 XOJHPVYUYLWBSO-UHFFFAOYSA-N 0.000 description 2
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 2
- BPYHGTCRXDWOIQ-UHFFFAOYSA-N 3-nitropyridin-2-amine Chemical compound NC1=NC=CC=C1[N+]([O-])=O BPYHGTCRXDWOIQ-UHFFFAOYSA-N 0.000 description 2
- HYXCGHXNNZRLRP-UHFFFAOYSA-N 4-(4-benzyl-3-oxopiperazin-1-yl)benzaldehyde Chemical compound C(C1=CC=CC=C1)N1C(CN(CC1)C1=CC=C(C=O)C=C1)=O HYXCGHXNNZRLRP-UHFFFAOYSA-N 0.000 description 2
- JDWZUVQRUPAVPK-UHFFFAOYSA-N 4-(4-benzylpiperazin-1-yl)benzaldehyde Chemical compound C1=CC(C=O)=CC=C1N1CCN(CC=2C=CC=CC=2)CC1 JDWZUVQRUPAVPK-UHFFFAOYSA-N 0.000 description 2
- IOBXFDHJVBLVMT-UHFFFAOYSA-N 4-(4-methyl-3-oxopiperazin-1-yl)benzaldehyde Chemical compound C1C(=O)N(C)CCN1C1=CC=C(C=O)C=C1 IOBXFDHJVBLVMT-UHFFFAOYSA-N 0.000 description 2
- DTAODPWLQDLNCE-UHFFFAOYSA-N 4-[(4-aminopiperidin-1-yl)methyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC(CN2CCC(N)CC2)=C1 DTAODPWLQDLNCE-UHFFFAOYSA-N 0.000 description 2
- FHQNHLDDKIIIMS-UHFFFAOYSA-N 4-[2-methyl-4-(1,3-thiazol-2-ylmethyl)piperazin-1-yl]benzaldehyde Chemical compound CC1N(CCN(C1)CC=1SC=CN=1)C1=CC=C(C=O)C=C1 FHQNHLDDKIIIMS-UHFFFAOYSA-N 0.000 description 2
- CAOQPURIJKFJHO-UHFFFAOYSA-N 4-[3-methyl-4-(1,3-thiazol-2-ylmethyl)piperazin-1-yl]benzaldehyde Chemical compound CC1CN(CCN1CC=1SC=CN=1)C1=CC=C(C=O)C=C1 CAOQPURIJKFJHO-UHFFFAOYSA-N 0.000 description 2
- DFPQQRNYNQBFBC-UHFFFAOYSA-N 4-[3-methyl-4-(pyridin-3-ylmethyl)piperazin-1-yl]benzaldehyde Chemical compound CC1CN(CCN1CC=1C=NC=CC=1)C1=CC=C(C=O)C=C1 DFPQQRNYNQBFBC-UHFFFAOYSA-N 0.000 description 2
- SYZZGTLJHGOQJJ-UHFFFAOYSA-N 4-[3-oxo-4-(2-propan-2-yloxyethyl)piperazin-1-yl]benzaldehyde Chemical compound CC(C)OCCN1C(CN(CC1)C1=CC=C(C=O)C=C1)=O SYZZGTLJHGOQJJ-UHFFFAOYSA-N 0.000 description 2
- KMIYTQZRVQSWGI-UHFFFAOYSA-N 4-[4-(1,3-thiazol-2-ylmethyl)piperazin-1-yl]benzaldehyde Chemical compound S1C(=NC=C1)CN1CCN(CC1)C1=CC=C(C=O)C=C1 KMIYTQZRVQSWGI-UHFFFAOYSA-N 0.000 description 2
- AAGQKDRPZRCNGW-UHFFFAOYSA-N 4-[4-(1,3-thiazol-4-ylmethyl)piperazin-1-yl]benzaldehyde Chemical compound S1C=NC(=C1)CN1CCN(CC1)C1=CC=C(C=O)C=C1 AAGQKDRPZRCNGW-UHFFFAOYSA-N 0.000 description 2
- GDTHZMDXDPZOOF-UHFFFAOYSA-N 4-[4-(1,3-thiazol-5-ylmethyl)piperazin-1-yl]benzaldehyde Chemical compound S1C=NC=C1CN1CCN(CC1)C1=CC=C(C=O)C=C1 GDTHZMDXDPZOOF-UHFFFAOYSA-N 0.000 description 2
- DYEUGIHWKIXYMS-UHFFFAOYSA-N 4-[4-(1H-imidazol-5-ylmethyl)piperazin-1-yl]benzaldehyde Chemical compound N1C=NC(=C1)CN1CCN(CC1)C1=CC=C(C=O)C=C1 DYEUGIHWKIXYMS-UHFFFAOYSA-N 0.000 description 2
- BNLXBFGMOKXIHA-UHFFFAOYSA-N 4-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]benzaldehyde Chemical compound C1CN(C(=O)C(C)(C)C)CCN1C1=CC=C(C=O)C=C1 BNLXBFGMOKXIHA-UHFFFAOYSA-N 0.000 description 2
- XTLICSKNJWTVQE-UHFFFAOYSA-N 4-[4-(2-ethoxyethyl)-1,4-diazepan-1-yl]benzaldehyde Chemical compound C(C)OCCN1CCN(CCC1)C1=CC=C(C=O)C=C1 XTLICSKNJWTVQE-UHFFFAOYSA-N 0.000 description 2
- OZUCZRIYWTUWHD-UHFFFAOYSA-N 4-[4-(2-ethoxyethyl)-3-oxopiperazin-1-yl]benzaldehyde Chemical compound C(C)OCCN1C(CN(CC1)C1=CC=C(C=O)C=C1)=O OZUCZRIYWTUWHD-UHFFFAOYSA-N 0.000 description 2
- CIXAFSCAKNBBNS-UHFFFAOYSA-N 4-[4-(2-ethoxyethyl)piperazin-1-yl]benzaldehyde Chemical compound C(C)OCCN1CCN(CC1)C1=CC=C(C=O)C=C1 CIXAFSCAKNBBNS-UHFFFAOYSA-N 0.000 description 2
- AQZJBLZPXDMEBS-UHFFFAOYSA-N 4-[4-(2-ethoxyethyl)piperidin-1-yl]benzaldehyde Chemical compound C(C)OCCC1CCN(CC1)C1=CC=C(C=O)C=C1 AQZJBLZPXDMEBS-UHFFFAOYSA-N 0.000 description 2
- ABFLVTWNJNJGLM-UHFFFAOYSA-N 4-[4-(2-methoxyethyl)-1,4-diazepan-1-yl]benzaldehyde Chemical compound COCCN1CCN(CCC1)C1=CC=C(C=O)C=C1 ABFLVTWNJNJGLM-UHFFFAOYSA-N 0.000 description 2
- HFMGRIRITOBLSR-UHFFFAOYSA-N 4-[4-(2-methoxyethyl)-2-methylpiperazin-1-yl]benzaldehyde Chemical compound COCCN1CC(N(CC1)C1=CC=C(C=O)C=C1)C HFMGRIRITOBLSR-UHFFFAOYSA-N 0.000 description 2
- QAMWDTPRRMRFIW-UHFFFAOYSA-N 4-[4-(2-propan-2-yloxyethyl)-1,4-diazepan-1-yl]benzaldehyde Chemical compound CC(C)OCCN1CCN(CCC1)C1=CC=C(C=O)C=C1 QAMWDTPRRMRFIW-UHFFFAOYSA-N 0.000 description 2
- LFVJNHWRYMWHCH-UHFFFAOYSA-N 4-[4-(2-propan-2-yloxyethyl)piperazin-1-yl]benzaldehyde Chemical compound CC(C)OCCN1CCN(CC1)C1=CC=C(C=O)C=C1 LFVJNHWRYMWHCH-UHFFFAOYSA-N 0.000 description 2
- OSZWTCZNGGXJRS-UHFFFAOYSA-N 4-[4-(3-hydroxypropyl)piperazin-1-yl]benzaldehyde Chemical compound OCCCN1CCN(CC1)C1=CC=C(C=O)C=C1 OSZWTCZNGGXJRS-UHFFFAOYSA-N 0.000 description 2
- KQMMVHXSQUGVLF-UHFFFAOYSA-N 4-[4-(3-methoxypropyl)-2-methylpiperazin-1-yl]benzaldehyde Chemical compound COCCCN1CC(N(CC1)C1=CC=C(C=O)C=C1)C KQMMVHXSQUGVLF-UHFFFAOYSA-N 0.000 description 2
- SDVHDGOBUAPEGW-UHFFFAOYSA-N 4-[4-(3-methoxypropyl)-3-methylpiperazin-1-yl]benzaldehyde Chemical compound COCCCN1C(CN(CC1)C1=CC=C(C=O)C=C1)C SDVHDGOBUAPEGW-UHFFFAOYSA-N 0.000 description 2
- KFUAPMMTQZIMGQ-UHFFFAOYSA-N 4-[4-(3-methoxypropyl)-3-oxopiperazin-1-yl]benzaldehyde Chemical compound COCCCN1C(CN(CC1)C1=CC=C(C=O)C=C1)=O KFUAPMMTQZIMGQ-UHFFFAOYSA-N 0.000 description 2
- FICCAQNPNIOEGC-UHFFFAOYSA-N 4-[4-(3-methoxypropyl)piperazin-1-yl]benzaldehyde Chemical compound COCCCN1CCN(CC1)C1=CC=C(C=O)C=C1 FICCAQNPNIOEGC-UHFFFAOYSA-N 0.000 description 2
- HIXNSVXOVIJQCA-UHFFFAOYSA-N 4-[4-(4-methoxybutyl)piperazin-1-yl]benzaldehyde Chemical compound COCCCCN1CCN(CC1)C1=CC=C(C=O)C=C1 HIXNSVXOVIJQCA-UHFFFAOYSA-N 0.000 description 2
- DEZXSKIUVHHLKG-UHFFFAOYSA-N 4-[4-(pyrazin-2-ylmethyl)piperazin-1-yl]benzaldehyde Chemical compound N1=C(C=NC=C1)CN1CCN(CC1)C1=CC=C(C=O)C=C1 DEZXSKIUVHHLKG-UHFFFAOYSA-N 0.000 description 2
- RNULFTKVCHEKNT-UHFFFAOYSA-N 4-[4-(pyridine-3-carbonyl)piperazin-1-yl]benzaldehyde Chemical compound N1=CC(=CC=C1)C(=O)N1CCN(CC1)C1=CC=C(C=O)C=C1 RNULFTKVCHEKNT-UHFFFAOYSA-N 0.000 description 2
- QRVZMDTUMQLFHG-UHFFFAOYSA-N 4-[4-(pyridine-4-carbonyl)piperazin-1-yl]benzaldehyde Chemical compound N1=CC=C(C=C1)C(=O)N1CCN(CC1)C1=CC=C(C=O)C=C1 QRVZMDTUMQLFHG-UHFFFAOYSA-N 0.000 description 2
- VCRIARBCVGEGPE-UHFFFAOYSA-N 4-[4-[(1-methylimidazol-2-yl)methyl]piperazin-1-yl]benzaldehyde Chemical compound CN1C(=NC=C1)CN1CCN(CC1)C1=CC=C(C=O)C=C1 VCRIARBCVGEGPE-UHFFFAOYSA-N 0.000 description 2
- WUHZZMHJIGMJCM-UHFFFAOYSA-N 4-[4-[(3,5-dimethyl-1,2-oxazol-4-yl)methyl]piperazin-1-yl]benzaldehyde Chemical compound CC1=NOC(=C1CN1CCN(CC1)C1=CC=C(C=O)C=C1)C WUHZZMHJIGMJCM-UHFFFAOYSA-N 0.000 description 2
- FPBGFBLEOXKVNJ-UHFFFAOYSA-N 4-[4-[(5-methylfuran-2-yl)methyl]piperazin-1-yl]benzaldehyde Chemical compound CC1=CC=C(O1)CN1CCN(CC1)C1=CC=C(C=O)C=C1 FPBGFBLEOXKVNJ-UHFFFAOYSA-N 0.000 description 2
- PUABAKPMRBZYOU-UHFFFAOYSA-N 4-[4-[(5-methylpyridin-2-yl)methyl]piperazin-1-yl]benzaldehyde Chemical compound CC=1C=CC(=NC=1)CN1CCN(CC1)C1=CC=C(C=O)C=C1 PUABAKPMRBZYOU-UHFFFAOYSA-N 0.000 description 2
- QYXVLGPSBAMJRU-UHFFFAOYSA-N 4-[4-[(6-methylpyridin-3-yl)methyl]piperazin-1-yl]benzaldehyde Chemical compound CC1=CC=C(C=N1)CN1CCN(CC1)C1=CC=C(C=O)C=C1 QYXVLGPSBAMJRU-UHFFFAOYSA-N 0.000 description 2
- HJDNLORREQGTBV-UHFFFAOYSA-N 4-[4-[2-[(2-methylpyrazol-3-yl)amino]ethyl]piperazin-1-yl]benzaldehyde Chemical compound CN1N=CC=C1NCCN1CCN(CC1)C1=CC=C(C=O)C=C1 HJDNLORREQGTBV-UHFFFAOYSA-N 0.000 description 2
- XQTUJLGZWBTKDN-UHFFFAOYSA-N 4-[[4-(pyrimidin-5-ylmethyl)piperazin-1-yl]methyl]benzaldehyde Chemical compound N1=CN=CC(=C1)CN1CCN(CC1)CC1=CC=C(C=O)C=C1 XQTUJLGZWBTKDN-UHFFFAOYSA-N 0.000 description 2
- DIRINUVNYFAWQF-UHFFFAOYSA-N 4-chloro-3-nitropyridin-2-amine Chemical compound NC1=NC=CC(Cl)=C1[N+]([O-])=O DIRINUVNYFAWQF-UHFFFAOYSA-N 0.000 description 2
- BYZPHVDZNCDKBA-UHFFFAOYSA-N 4-fluoro-2-[4-(2-methoxyethyl)piperazin-1-yl]benzaldehyde Chemical compound FC1=CC(=C(C=O)C=C1)N1CCN(CC1)CCOC BYZPHVDZNCDKBA-UHFFFAOYSA-N 0.000 description 2
- LGRQUXHYJBFGTM-UHFFFAOYSA-N 4H-imidazole Chemical compound C1C=NC=N1 LGRQUXHYJBFGTM-UHFFFAOYSA-N 0.000 description 2
- SYBOEAMERMZLDN-UHFFFAOYSA-N 5-chloro-4-N-(1-methylpiperidin-4-yl)-3-nitropyridine-2,4-diamine Chemical compound ClC=1C(=C(C(=NC=1)N)[N+](=O)[O-])NC1CCN(CC1)C SYBOEAMERMZLDN-UHFFFAOYSA-N 0.000 description 2
- OUDFNZMQXZILJD-UHFFFAOYSA-N 5-methyl-2-furaldehyde Chemical compound CC1=CC=C(C=O)O1 OUDFNZMQXZILJD-UHFFFAOYSA-N 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 2
- 208000008190 Agammaglobulinemia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 2
- CGXAUQQVPUGHEB-UHFFFAOYSA-N BrC=1C(=C(C(=NC=1)N)[N+](=O)[O-])NC1CCN(CC1)CCC Chemical compound BrC=1C(=C(C(=NC=1)N)[N+](=O)[O-])NC1CCN(CC1)CCC CGXAUQQVPUGHEB-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 2
- 208000012309 Linear IgA disease Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000003926 Myelitis Diseases 0.000 description 2
- DSSKLTAHHALFRW-UHFFFAOYSA-N N-cyclohexylpiperidine Chemical compound C1CCCCC1N1CCCCC1 DSSKLTAHHALFRW-UHFFFAOYSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108010006700 Receptor Tyrosine Kinase-like Orphan Receptors Proteins 0.000 description 2
- 102000005435 Receptor Tyrosine Kinase-like Orphan Receptors Human genes 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 206010042276 Subacute endocarditis Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 201000000053 blastoma Diseases 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004252 chorionic villi Anatomy 0.000 description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 201000008184 embryoma Diseases 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 208000024519 eye neoplasm Diseases 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000011223 gene expression profiling Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
- 201000008106 ocular cancer Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 208000005987 polymyositis Diseases 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 201000005671 spondyloarthropathy Diseases 0.000 description 2
- 208000008467 subacute bacterial endocarditis Diseases 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 206010043207 temporal arteritis Diseases 0.000 description 2
- KEVJRVHXORTWTR-UHFFFAOYSA-N tert-butyl 4-methylsulfonylpiperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(S(C)(=O)=O)CC1 KEVJRVHXORTWTR-UHFFFAOYSA-N 0.000 description 2
- DQQJBEAXSOOCPG-ZETCQYMHSA-N tert-butyl n-[(3s)-pyrrolidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1CCNC1 DQQJBEAXSOOCPG-ZETCQYMHSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- MLFHQCXQJORNNE-KLXURFKVSA-N (3S)-1-propylpyrrolidin-3-amine dihydrochloride Chemical compound Cl.Cl.C(CC)N1C[C@H](CC1)N MLFHQCXQJORNNE-KLXURFKVSA-N 0.000 description 1
- QQBSLNKWDXZLKL-ZETCQYMHSA-N (3s)-1-propylpyrrolidin-3-amine Chemical compound CCCN1CC[C@H](N)C1 QQBSLNKWDXZLKL-ZETCQYMHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- HMTUBXVXHHITGO-UHFFFAOYSA-N 1,3,5-trimethylpyrazole-4-carbaldehyde Chemical compound CC1=NN(C)C(C)=C1C=O HMTUBXVXHHITGO-UHFFFAOYSA-N 0.000 description 1
- WRFKSVINLIQRKF-UHFFFAOYSA-N 1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC=N1 WRFKSVINLIQRKF-UHFFFAOYSA-N 0.000 description 1
- ZXRLWHGLEJGMNO-UHFFFAOYSA-N 1,3-thiazole-5-carbaldehyde Chemical compound O=CC1=CN=CS1 ZXRLWHGLEJGMNO-UHFFFAOYSA-N 0.000 description 1
- CORMODVUQAFUOY-UHFFFAOYSA-N 1-(1h-imidazol-5-ylmethyl)piperazine Chemical compound C=1NC=NC=1CN1CCNCC1 CORMODVUQAFUOY-UHFFFAOYSA-N 0.000 description 1
- PCECTGZMOZXPGY-UHFFFAOYSA-N 1-(2-ethoxyethyl)-1,4-diazepane dihydrochloride Chemical compound Cl.Cl.C(C)OCCN1CCNCCC1 PCECTGZMOZXPGY-UHFFFAOYSA-N 0.000 description 1
- TXQLUKMSYDOGDH-UHFFFAOYSA-N 1-(2-ethoxyethyl)piperazine Chemical compound CCOCCN1CCNCC1 TXQLUKMSYDOGDH-UHFFFAOYSA-N 0.000 description 1
- UUNUPVMSAWYGEJ-UHFFFAOYSA-N 1-(2-ethoxyethyl)piperazine dihydrochloride Chemical compound Cl.Cl.C(C)OCCN1CCNCC1 UUNUPVMSAWYGEJ-UHFFFAOYSA-N 0.000 description 1
- FCVVYNHYOYDIMQ-UHFFFAOYSA-N 1-(2-methoxyethyl)-1,4-diazepane dihydrochloride Chemical compound Cl.Cl.COCCN1CCCNCC1 FCVVYNHYOYDIMQ-UHFFFAOYSA-N 0.000 description 1
- WGOQNROQRIISTQ-UHFFFAOYSA-N 1-(2-methoxyethyl)-2-methylpiperazine Chemical compound COCCN1CCNCC1C WGOQNROQRIISTQ-UHFFFAOYSA-N 0.000 description 1
- YWPDHZQNTUFAGP-UHFFFAOYSA-N 1-(2-methoxyethyl)-3-methylpiperazine Chemical compound COCCN1CCNC(C)C1 YWPDHZQNTUFAGP-UHFFFAOYSA-N 0.000 description 1
- ILMDRDDKNWKCNX-UHFFFAOYSA-N 1-(2-methoxyethyl)piperidin-4-amine Chemical compound COCCN1CCC(N)CC1 ILMDRDDKNWKCNX-UHFFFAOYSA-N 0.000 description 1
- GTBCSAQQLQOECO-UHFFFAOYSA-N 1-(2-propan-2-yloxyethyl)-1,4-diazepane Chemical compound CC(C)OCCN1CCCNCC1 GTBCSAQQLQOECO-UHFFFAOYSA-N 0.000 description 1
- HVZJSUVDFMFZCP-UHFFFAOYSA-N 1-(2-propan-2-yloxyethyl)piperazine Chemical compound CC(C)OCCN1CCNCC1 HVZJSUVDFMFZCP-UHFFFAOYSA-N 0.000 description 1
- BZJXMXBJBWFCST-UHFFFAOYSA-N 1-(3-methoxypropyl)-2-methylpiperazine Chemical compound COCCCN1CCNCC1C BZJXMXBJBWFCST-UHFFFAOYSA-N 0.000 description 1
- FMTAWQQGASKBBA-UHFFFAOYSA-N 1-(3-methoxypropyl)-3-methylpiperazine Chemical compound COCCCN1CCNC(C)C1 FMTAWQQGASKBBA-UHFFFAOYSA-N 0.000 description 1
- GWWCQKPWZIASLS-UHFFFAOYSA-N 1-(3-methoxypropyl)piperazine Chemical compound COCCCN1CCNCC1 GWWCQKPWZIASLS-UHFFFAOYSA-N 0.000 description 1
- RCUHJBWDIITPIC-UHFFFAOYSA-N 1-(4-methoxybutyl)piperazine Chemical compound COCCCCN1CCNCC1 RCUHJBWDIITPIC-UHFFFAOYSA-N 0.000 description 1
- IYYXLZOFUOPDAM-UHFFFAOYSA-N 1-[(1,3,5-trimethylpyrazol-4-yl)methyl]piperidin-4-amine Chemical compound CC1=NN(C)C(C)=C1CN1CCC(N)CC1 IYYXLZOFUOPDAM-UHFFFAOYSA-N 0.000 description 1
- SOCFBKAXXSIIFD-UHFFFAOYSA-N 1-[(1-methylimidazol-2-yl)methyl]piperazine Chemical compound CN1C=CN=C1CN1CCNCC1 SOCFBKAXXSIIFD-UHFFFAOYSA-N 0.000 description 1
- YJXYDJCNUAXWKY-UHFFFAOYSA-N 1-[(5-methylfuran-2-yl)methyl]piperazine Chemical compound O1C(C)=CC=C1CN1CCNCC1 YJXYDJCNUAXWKY-UHFFFAOYSA-N 0.000 description 1
- LYYZZDJUCFDNCR-UHFFFAOYSA-N 1-[(5-methylpyridin-2-yl)methyl]piperazine Chemical compound N1=CC(C)=CC=C1CN1CCNCC1 LYYZZDJUCFDNCR-UHFFFAOYSA-N 0.000 description 1
- QAQSWCKYRYGATB-UHFFFAOYSA-N 1-[(6-methylpyridin-2-yl)methyl]piperazine Chemical compound CC1=CC=CC(CN2CCNCC2)=N1 QAQSWCKYRYGATB-UHFFFAOYSA-N 0.000 description 1
- WARIMOYXTMFETA-UHFFFAOYSA-N 1-[(6-methylpyridin-3-yl)methyl]piperazine Chemical compound C1=NC(C)=CC=C1CN1CCNCC1 WARIMOYXTMFETA-UHFFFAOYSA-N 0.000 description 1
- LQVJNGKUEHBOAN-UHFFFAOYSA-N 1-[2-(2-methoxyethoxy)ethyl]piperazine Chemical compound COCCOCCN1CCNCC1 LQVJNGKUEHBOAN-UHFFFAOYSA-N 0.000 description 1
- IQXXEPZFOOTTBA-UHFFFAOYSA-N 1-benzylpiperazine Chemical compound C=1C=CC=CC=1CN1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- GZWFMQMAEUUNCC-UHFFFAOYSA-N 1-cyclohexylpiperidin-4-amine Chemical compound C1CC(N)CCN1C1CCCCC1 GZWFMQMAEUUNCC-UHFFFAOYSA-N 0.000 description 1
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 1
- UEBFLTZXUXZPJO-UHFFFAOYSA-N 1-methylimidazole-2-carbaldehyde Chemical compound CN1C=CN=C1C=O UEBFLTZXUXZPJO-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- PKDPUENCROCRCH-UHFFFAOYSA-N 1-piperazin-1-ylethanone Chemical compound CC(=O)N1CCNCC1 PKDPUENCROCRCH-UHFFFAOYSA-N 0.000 description 1
- ZRQQXFMGYSOKDF-UHFFFAOYSA-N 1-propan-2-ylpiperidin-4-amine Chemical compound CC(C)N1CCC(N)CC1 ZRQQXFMGYSOKDF-UHFFFAOYSA-N 0.000 description 1
- ZCYVGFQRDRGDJM-UHFFFAOYSA-N 1-propylpiperidin-4-amine Chemical compound CCCN1CCC(N)CC1 ZCYVGFQRDRGDJM-UHFFFAOYSA-N 0.000 description 1
- ZQEXIXXJFSQPNA-UHFFFAOYSA-N 1h-imidazole-5-carbaldehyde Chemical compound O=CC1=CNC=N1 ZQEXIXXJFSQPNA-UHFFFAOYSA-N 0.000 description 1
- BADGSAIBBNOSKA-UHFFFAOYSA-N 2,2-dimethyl-1-piperazin-1-ylpropan-1-one 2,2,2-trifluoroacetic acid Chemical compound FC(C(=O)O)(F)F.CC(C(=O)N1CCNCC1)(C)C BADGSAIBBNOSKA-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- WDBAXYQUOZDFOJ-UHFFFAOYSA-N 2,3-difluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1F WDBAXYQUOZDFOJ-UHFFFAOYSA-N 0.000 description 1
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 1
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 1
- FCHYIMQJCGYDPR-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethyl methanesulfonate Chemical compound COCCOCCOS(C)(=O)=O FCHYIMQJCGYDPR-UHFFFAOYSA-N 0.000 description 1
- ZGYLBJLUOKJLRB-UHFFFAOYSA-N 2-(4-aminopiperidin-1-yl)acetonitrile Chemical compound NC1CCN(CC#N)CC1 ZGYLBJLUOKJLRB-UHFFFAOYSA-N 0.000 description 1
- NEPNZBBYKHIRKO-UHFFFAOYSA-N 2-(piperazin-1-ylmethyl)-1,3-thiazole Chemical compound N=1C=CSC=1CN1CCNCC1 NEPNZBBYKHIRKO-UHFFFAOYSA-N 0.000 description 1
- UMSBILFYXUYRGS-UHFFFAOYSA-N 2-(piperazin-1-ylmethyl)pyrazine Chemical compound C=1N=CC=NC=1CN1CCNCC1 UMSBILFYXUYRGS-UHFFFAOYSA-N 0.000 description 1
- VHXKWGNDBTZVOC-UHFFFAOYSA-N 2-[(2-methylpiperazin-1-yl)methyl]-1,3-thiazole Chemical compound CC1CNCCN1CC1=NC=CS1 VHXKWGNDBTZVOC-UHFFFAOYSA-N 0.000 description 1
- OISOWCVOCXYXIZ-UHFFFAOYSA-N 2-[(3-methylpiperazin-1-yl)methyl]-1,3-thiazole Chemical compound C1CNC(C)CN1CC1=NC=CS1 OISOWCVOCXYXIZ-UHFFFAOYSA-N 0.000 description 1
- KVNHEAITBUBDQZ-UHFFFAOYSA-N 2-[4-[(2-amino-5-bromo-3-nitropyridin-4-yl)amino]piperidin-1-yl]acetonitrile Chemical compound NC1=NC=C(C(=C1[N+](=O)[O-])NC1CCN(CC1)CC#N)Br KVNHEAITBUBDQZ-UHFFFAOYSA-N 0.000 description 1
- KLBROENOTRWYOO-UHFFFAOYSA-N 2-[4-[(2-amino-5-chloro-3-nitropyridin-4-yl)amino]piperidin-1-yl]acetonitrile Chemical compound NC1=NC=C(C(=C1[N+](=O)[O-])NC1CCN(CC1)CC#N)Cl KLBROENOTRWYOO-UHFFFAOYSA-N 0.000 description 1
- MPXVTXBMYIRQGB-UHFFFAOYSA-N 2-bromo-1-methoxybutane Chemical group CCC(Br)COC MPXVTXBMYIRQGB-UHFFFAOYSA-N 0.000 description 1
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- PYNYHMRMZOGVML-UHFFFAOYSA-N 2-bromopropanenitrile Chemical compound CC(Br)C#N PYNYHMRMZOGVML-UHFFFAOYSA-N 0.000 description 1
- RNIPDCAROPTDSD-UHFFFAOYSA-N 2-fluoro-4-[4-(2-methoxyethyl)piperazin-1-yl]benzaldehyde Chemical compound FC1=C(C=O)C=CC(=C1)N1CCN(CC1)CCOC RNIPDCAROPTDSD-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical class C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- PBHYSKKYTJIHKY-UHFFFAOYSA-N 2-methyl-1-(pyridin-3-ylmethyl)piperazine Chemical compound CC1CNCCN1CC1=CC=CN=C1 PBHYSKKYTJIHKY-UHFFFAOYSA-N 0.000 description 1
- QZLOCOJUKUFIOS-UHFFFAOYSA-N 2-methyl-N-(2-piperazin-1-ylethyl)pyrazol-3-amine Chemical compound CN1N=CC=C1NCCN1CCNCC1 QZLOCOJUKUFIOS-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- LDSQQXKSEFZAPE-UHFFFAOYSA-N 2-piperidin-4-ylethanol Chemical compound OCCC1CCNCC1 LDSQQXKSEFZAPE-UHFFFAOYSA-N 0.000 description 1
- HCGFUIQPSOCUHI-UHFFFAOYSA-N 2-propan-2-yloxyethanol Chemical compound CC(C)OCCO HCGFUIQPSOCUHI-UHFFFAOYSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- LJPFGGDQLGMPPG-UHFFFAOYSA-N 3,5-dimethyl-4-(piperazin-1-ylmethyl)-1,2-oxazole Chemical compound CC1=NOC(C)=C1CN1CCNCC1 LJPFGGDQLGMPPG-UHFFFAOYSA-N 0.000 description 1
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 1
- QULHFVSMXDSLFU-UHFFFAOYSA-N 3-[4-[(2-amino-5-bromo-3-nitropyridin-4-yl)amino]piperidin-1-yl]propanenitrile Chemical compound NC1=NC=C(C(=C1[N+](=O)[O-])NC1CCN(CC1)CCC#N)Br QULHFVSMXDSLFU-UHFFFAOYSA-N 0.000 description 1
- NDWLQXZVMIEITD-UHFFFAOYSA-N 3-[4-[(2-amino-5-chloro-3-nitropyridin-4-yl)amino]piperidin-1-yl]propanenitrile Chemical compound NC1=NC=C(C(=C1[N+](=O)[O-])NC1CCN(CC1)CCC#N)Cl NDWLQXZVMIEITD-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- CQZIEDXCLQOOEH-UHFFFAOYSA-N 3-bromopropanenitrile Chemical compound BrCCC#N CQZIEDXCLQOOEH-UHFFFAOYSA-N 0.000 description 1
- GVRVLFRTPCZCQZ-UHFFFAOYSA-N 3-fluoro-4-[4-(2-methoxyethyl)piperazin-1-yl]benzaldehyde Chemical compound FC=1C=C(C=O)C=CC=1N1CCN(CC1)CCOC GVRVLFRTPCZCQZ-UHFFFAOYSA-N 0.000 description 1
- RBIGKSZIQCTIJF-UHFFFAOYSA-N 3-formylthiophene Chemical compound O=CC=1C=CSC=1 RBIGKSZIQCTIJF-UHFFFAOYSA-N 0.000 description 1
- WFENZZMHMOIQDR-UHFFFAOYSA-N 3-methoxy-4-[4-(2-methoxyethyl)piperazin-1-yl]benzaldehyde Chemical compound COC=1C=C(C=O)C=CC=1N1CCN(CC1)CCOC WFENZZMHMOIQDR-UHFFFAOYSA-N 0.000 description 1
- JDFDHBSESGTDAL-UHFFFAOYSA-N 3-methoxypropan-1-ol Chemical compound COCCCO JDFDHBSESGTDAL-UHFFFAOYSA-N 0.000 description 1
- JSMDUOFOPDSKIQ-UHFFFAOYSA-N 3-methoxypropanoyl chloride Chemical compound COCCC(Cl)=O JSMDUOFOPDSKIQ-UHFFFAOYSA-N 0.000 description 1
- LWEOFVINMVZGAS-UHFFFAOYSA-N 3-piperazin-1-ylpropan-1-ol Chemical compound OCCCN1CCNCC1 LWEOFVINMVZGAS-UHFFFAOYSA-N 0.000 description 1
- MVOFPBMQTXKONX-UHFFFAOYSA-N 3-piperazin-1-ylpropanenitrile Chemical compound N#CCCN1CCNCC1 MVOFPBMQTXKONX-UHFFFAOYSA-N 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- CRRAQLWJVYODCL-UHFFFAOYSA-N 4,5-dichloropyridin-2-amine Chemical compound NC1=CC(Cl)=C(Cl)C=N1 CRRAQLWJVYODCL-UHFFFAOYSA-N 0.000 description 1
- JCPJBVUIQXVBCD-UHFFFAOYSA-N 4-(2-ethoxyethyl)piperidine;hydrochloride Chemical compound Cl.CCOCCC1CCNCC1 JCPJBVUIQXVBCD-UHFFFAOYSA-N 0.000 description 1
- LMGSBYGUGOVCNH-UHFFFAOYSA-N 4-(2-methoxyethyl)piperidine;hydrochloride Chemical compound Cl.COCCC1CCNCC1 LMGSBYGUGOVCNH-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- UTDGWGHLQNPKOZ-UHFFFAOYSA-N 4-(3-oxopiperazin-1-yl)benzaldehyde Chemical compound C1=CC(C=O)=CC=C1N1CC(=O)NCC1 UTDGWGHLQNPKOZ-UHFFFAOYSA-N 0.000 description 1
- DYRIBKWUSUQUNN-UHFFFAOYSA-N 4-(4-acetylpiperazin-1-yl)benzaldehyde Chemical compound C1CN(C(=O)C)CCN1C1=CC=C(C=O)C=C1 DYRIBKWUSUQUNN-UHFFFAOYSA-N 0.000 description 1
- UXVDOPUAJVRFDG-UHFFFAOYSA-N 4-(4-ethylpiperazin-1-yl)benzaldehyde Chemical compound C1CN(CC)CCN1C1=CC=C(C=O)C=C1 UXVDOPUAJVRFDG-UHFFFAOYSA-N 0.000 description 1
- MRMHNZCHZCRCAV-UHFFFAOYSA-N 4-(4-methyl-1,4-diazepan-1-yl)benzaldehyde Chemical compound C1CN(C)CCCN1C1=CC=C(C=O)C=C1 MRMHNZCHZCRCAV-UHFFFAOYSA-N 0.000 description 1
- CUPYRHQDTWJMIO-UHFFFAOYSA-N 4-(4-methylsulfonylpiperazin-1-yl)benzaldehyde Chemical compound C1CN(S(=O)(=O)C)CCN1C1=CC=C(C=O)C=C1 CUPYRHQDTWJMIO-UHFFFAOYSA-N 0.000 description 1
- WSKMLZRCGUFTCC-UHFFFAOYSA-N 4-(4-pyrazin-2-ylpiperazin-1-yl)benzaldehyde Chemical compound N1=C(C=NC=C1)N1CCN(CC1)C1=CC=C(C=O)C=C1 WSKMLZRCGUFTCC-UHFFFAOYSA-N 0.000 description 1
- WNBIHCLREZTCBN-UHFFFAOYSA-N 4-(4-pyridin-3-ylpiperazin-1-yl)benzaldehyde Chemical compound N1=CC(=CC=C1)N1CCN(CC1)C1=CC=C(C=O)C=C1 WNBIHCLREZTCBN-UHFFFAOYSA-N 0.000 description 1
- SERCEXOFMLDXKE-UHFFFAOYSA-N 4-(4-pyridin-4-ylpiperazin-1-yl)benzaldehyde Chemical compound C1=CC(C=O)=CC=C1N1CCN(C=2C=CN=CC=2)CC1 SERCEXOFMLDXKE-UHFFFAOYSA-N 0.000 description 1
- YPURGTCZNXQZHR-UHFFFAOYSA-N 4-(5-oxo-1,4-diazepan-1-yl)benzaldehyde Chemical compound C1=CC(C=O)=CC=C1N1CCC(=O)NCC1 YPURGTCZNXQZHR-UHFFFAOYSA-N 0.000 description 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- YRQHAURHWDVVTK-UHFFFAOYSA-N 4-(piperazin-1-ylmethyl)-1,3-thiazole Chemical compound C=1SC=NC=1CN1CCNCC1 YRQHAURHWDVVTK-UHFFFAOYSA-N 0.000 description 1
- IFXBVTXYZRRRAE-UHFFFAOYSA-N 4-[4-(2-hydroxyethyl)piperazin-1-yl]benzaldehyde Chemical compound C1CN(CCO)CCN1C1=CC=C(C=O)C=C1 IFXBVTXYZRRRAE-UHFFFAOYSA-N 0.000 description 1
- PDGPATBIHPJYIZ-UHFFFAOYSA-N 4-[4-(2-hydroxyethyl)piperidin-1-yl]benzaldehyde Chemical compound C1CC(CCO)CCN1C1=CC=C(C=O)C=C1 PDGPATBIHPJYIZ-UHFFFAOYSA-N 0.000 description 1
- LHLYLDNJQFYBCO-UHFFFAOYSA-N 4-[4-(2-methoxyacetyl)piperazin-1-yl]benzaldehyde Chemical compound COCC(=O)N1CCN(CC1)C1=CC=C(C=O)C=C1 LHLYLDNJQFYBCO-UHFFFAOYSA-N 0.000 description 1
- FJDUJJSTYNXLJV-UHFFFAOYSA-N 4-[4-(2-methoxyethyl)-3-methylpiperazin-1-yl]benzaldehyde Chemical compound COCCN1C(CN(CC1)C1=CC=C(C=O)C=C1)C FJDUJJSTYNXLJV-UHFFFAOYSA-N 0.000 description 1
- NXCINCOIPOCMDN-UHFFFAOYSA-N 4-[4-(2-methoxyethyl)piperazin-1-yl]benzaldehyde Chemical compound C1CN(CCOC)CCN1C1=CC=C(C=O)C=C1 NXCINCOIPOCMDN-UHFFFAOYSA-N 0.000 description 1
- UFRIYNBOCWREIB-UHFFFAOYSA-N 4-[4-(2-methoxyethyl)piperidin-1-yl]benzaldehyde Chemical compound COCCC1CCN(CC1)C1=CC=C(C=O)C=C1 UFRIYNBOCWREIB-UHFFFAOYSA-N 0.000 description 1
- WWBRMSPFDRZAKI-UHFFFAOYSA-N 4-[4-(3-methoxypropanoyl)piperazin-1-yl]benzaldehyde Chemical compound COCCC(=O)N1CCN(CC1)C1=CC=C(C=O)C=C1 WWBRMSPFDRZAKI-UHFFFAOYSA-N 0.000 description 1
- BGRNSDDTGZCEDX-UHFFFAOYSA-N 4-[4-(pyridin-2-ylmethyl)piperazin-1-yl]benzaldehyde Chemical compound O=Cc1ccc(cc1)N1CCN(Cc2ccccn2)CC1 BGRNSDDTGZCEDX-UHFFFAOYSA-N 0.000 description 1
- LUTDEQSIEQKVOG-UHFFFAOYSA-N 4-[4-(pyridin-3-ylmethyl)piperazin-1-yl]benzaldehyde Chemical compound N1=CC(=CC=C1)CN1CCN(CC1)C1=CC=C(C=O)C=C1 LUTDEQSIEQKVOG-UHFFFAOYSA-N 0.000 description 1
- PEPZVCRNLZYERG-UHFFFAOYSA-N 4-[4-(pyridin-4-ylmethyl)piperazin-1-yl]benzaldehyde Chemical compound O=Cc1ccc(cc1)N1CCN(Cc2ccncc2)CC1 PEPZVCRNLZYERG-UHFFFAOYSA-N 0.000 description 1
- RFJXHPJHFSDHFQ-UHFFFAOYSA-N 4-[4-[(6-methylpyridin-2-yl)methyl]piperazin-1-yl]benzaldehyde Chemical compound CC1=CC=CC(=N1)CN1CCN(CC1)C1=CC=C(C=O)C=C1 RFJXHPJHFSDHFQ-UHFFFAOYSA-N 0.000 description 1
- GCODKVURYOYKEV-UHFFFAOYSA-N 4-[4-[2-(2-methoxyethoxy)ethyl]piperazin-1-yl]benzaldehyde Chemical compound COCCOCCN1CCN(CC1)C1=CC=C(C=O)C=C1 GCODKVURYOYKEV-UHFFFAOYSA-N 0.000 description 1
- ZXORZCWCNXLFMP-UHFFFAOYSA-N 4-[[4-[(2-amino-5-chloro-3-nitropyridin-4-yl)amino]piperidin-1-yl]methyl]-2-methoxyphenol Chemical compound NC1=NC=C(C(=C1[N+](=O)[O-])NC1CCN(CC1)CC1=CC(=C(C=C1)O)OC)Cl ZXORZCWCNXLFMP-UHFFFAOYSA-N 0.000 description 1
- RQMWVVBHJMUJNZ-UHFFFAOYSA-N 4-chloropyridin-2-amine Chemical compound NC1=CC(Cl)=CC=N1 RQMWVVBHJMUJNZ-UHFFFAOYSA-N 0.000 description 1
- FOAQOAXQMISINY-UHFFFAOYSA-N 4-morpholin-4-ylbenzaldehyde Chemical compound C1=CC(C=O)=CC=C1N1CCOCC1 FOAQOAXQMISINY-UHFFFAOYSA-N 0.000 description 1
- OLFBTDYWKRJXSH-UHFFFAOYSA-N 5-(piperazin-1-ylmethyl)-1,3-thiazole Chemical compound C=1N=CSC=1CN1CCNCC1 OLFBTDYWKRJXSH-UHFFFAOYSA-N 0.000 description 1
- OWSLFSNKXDONPQ-UHFFFAOYSA-N 5-(piperazin-1-ylmethyl)pyrimidine Chemical compound C=1N=CN=CC=1CN1CCNCC1 OWSLFSNKXDONPQ-UHFFFAOYSA-N 0.000 description 1
- OKHNANPSEBYVDZ-UHFFFAOYSA-N 5-bromo-4-N-(1-ethylpiperidin-4-yl)-3-nitropyridine-2,4-diamine Chemical compound BrC=1C(=C(C(=NC=1)N)[N+](=O)[O-])NC1CCN(CC1)CC OKHNANPSEBYVDZ-UHFFFAOYSA-N 0.000 description 1
- TVWNALKPRBNZJN-UHFFFAOYSA-N 5-bromo-4-N-[1-(cyclopropylmethyl)piperidin-4-yl]-3-nitropyridine-2,4-diamine Chemical compound C1CC1CN2CCC(CC2)NC3=C(C(=NC=C3Br)N)[N+](=O)[O-] TVWNALKPRBNZJN-UHFFFAOYSA-N 0.000 description 1
- ZIFOKHJJPSZBCL-UHFFFAOYSA-N 5-bromo-4-N-[1-[(4-methoxyphenyl)methyl]piperidin-4-yl]-3-nitropyridine-2,4-diamine Chemical compound COC1=CC=C(CN2CCC(CC2)NC2=C(C(N)=NC=C2Br)[N+]([O-])=O)C=C1 ZIFOKHJJPSZBCL-UHFFFAOYSA-N 0.000 description 1
- DDOFUMWLNSICHU-UHFFFAOYSA-N 5-bromo-4-chloropyridin-2-amine Chemical compound NC1=CC(Cl)=C(Br)C=N1 DDOFUMWLNSICHU-UHFFFAOYSA-N 0.000 description 1
- LVUIVVSOVBLPTN-UHFFFAOYSA-N 5-chloro-3-nitro-4-N-(1-propan-2-ylpiperidin-4-yl)pyridine-2,4-diamine Chemical compound ClC=1C(=C(C(=NC=1)N)[N+](=O)[O-])NC1CCN(CC1)C(C)C LVUIVVSOVBLPTN-UHFFFAOYSA-N 0.000 description 1
- ARLXZDLBRRNPTE-UHFFFAOYSA-N 5-chloro-3-nitro-4-N-(1-propylpiperidin-4-yl)pyridine-2,4-diamine Chemical compound ClC=1C(=C(C(=NC=1)N)[N+](=O)[O-])NC1CCN(CC1)CCC ARLXZDLBRRNPTE-UHFFFAOYSA-N 0.000 description 1
- FEFNCSLYXDJHGB-UHFFFAOYSA-N 5-chloro-3-nitro-4-N-[1-(thiophen-3-ylmethyl)piperidin-4-yl]pyridine-2,4-diamine Chemical compound ClC=1C(=C(C(=NC=1)N)[N+](=O)[O-])NC1CCN(CC1)CC1=CSC=C1 FEFNCSLYXDJHGB-UHFFFAOYSA-N 0.000 description 1
- MNBPNSLGIQXWSB-UHFFFAOYSA-N 5-chloro-4-N-(1-cyclohexylpiperidin-4-yl)-3-nitropyridine-2,4-diamine Chemical compound ClC=1C(=C(C(=NC=1)N)[N+](=O)[O-])NC1CCN(CC1)C1CCCCC1 MNBPNSLGIQXWSB-UHFFFAOYSA-N 0.000 description 1
- ZBSDNSCCMCNJMP-UHFFFAOYSA-N 5-chloro-4-N-(1-ethylpiperidin-4-yl)-3-nitropyridine-2,4-diamine Chemical compound ClC=1C(=C(C(=NC=1)N)[N+](=O)[O-])NC1CCN(CC1)CC ZBSDNSCCMCNJMP-UHFFFAOYSA-N 0.000 description 1
- WNONIEKKBCQRGV-LBPRGKRZSA-N 5-chloro-4-N-[(3S)-1-[(4-methoxyphenyl)methyl]pyrrolidin-3-yl]-3-nitropyridine-2,4-diamine Chemical compound ClC=1C(=C(C(=NC=1)N)[N+](=O)[O-])N[C@@H]1CN(CC1)CC1=CC=C(C=C1)OC WNONIEKKBCQRGV-LBPRGKRZSA-N 0.000 description 1
- MVHHTDAPNVMIFZ-UHFFFAOYSA-N 5-chloro-4-N-[1-(2,3-dihydro-1-benzofuran-5-ylmethyl)piperidin-4-yl]-3-nitropyridine-2,4-diamine Chemical compound ClC=1C(=C(C(=NC=1)N)[N+](=O)[O-])NC1CCN(CC1)CC=1C=CC2=C(CCO2)C=1 MVHHTDAPNVMIFZ-UHFFFAOYSA-N 0.000 description 1
- RKUSMXRHPZAZNV-UHFFFAOYSA-N 5-chloro-4-N-[1-(2-methoxyethyl)piperidin-4-yl]-3-nitropyridine-2,4-diamine Chemical compound ClC=1C(=C(C(=NC=1)N)[N+](=O)[O-])NC1CCN(CC1)CCOC RKUSMXRHPZAZNV-UHFFFAOYSA-N 0.000 description 1
- NUUSZOJGQIJZQR-UHFFFAOYSA-N 5-chloro-4-N-[1-(cyclopropylmethyl)piperidin-4-yl]-3-nitropyridine-2,4-diamine Chemical compound C1CC1CN2CCC(CC2)NC3=C(C(=NC=C3Cl)N)[N+](=O)[O-] NUUSZOJGQIJZQR-UHFFFAOYSA-N 0.000 description 1
- BVOGGBHEMHMNKW-UHFFFAOYSA-N 5-chloro-4-N-[1-[[4-(dimethylamino)phenyl]methyl]piperidin-4-yl]-3-nitropyridine-2,4-diamine Chemical compound ClC=1C(=C(C(=NC=1)N)[N+](=O)[O-])NC1CCN(CC1)CC1=CC=C(C=C1)N(C)C BVOGGBHEMHMNKW-UHFFFAOYSA-N 0.000 description 1
- IMWMEIWYPWVABQ-UHFFFAOYSA-N 6-methylpyridine-3-carbaldehyde Chemical compound CC1=CC=C(C=O)C=N1 IMWMEIWYPWVABQ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 description 1
- 206010069002 Autoimmune pancreatitis Diseases 0.000 description 1
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000009766 Blau syndrome Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- ZXZZRVXTLNJYOH-LURJTMIESA-N BrC=1C(=C(C(=NC=1)N)[N+](=O)[O-])N[C@@H]1CN(CC1)C Chemical compound BrC=1C(=C(C(=NC=1)N)[N+](=O)[O-])N[C@@H]1CN(CC1)C ZXZZRVXTLNJYOH-LURJTMIESA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 102100026008 Breakpoint cluster region protein Human genes 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 201000002829 CREST Syndrome Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000005024 Castleman disease Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- PRVRTYLITBJEMH-UHFFFAOYSA-N ClC1=CC(=NC=C1Cl)N.ClC1=CC(=NC=C1Cl)N[N+](=O)[O-] Chemical compound ClC1=CC(=NC=C1Cl)N.ClC1=CC(=NC=C1Cl)N[N+](=O)[O-] PRVRTYLITBJEMH-UHFFFAOYSA-N 0.000 description 1
- HEBUHZMNOXZMEU-UHFFFAOYSA-N ClC1=CC(=NC=C1Cl)N[N+](=O)[O-].ClC1=C(C(=NC=C1Cl)N)[N+](=O)[O-] Chemical compound ClC1=CC(=NC=C1Cl)N[N+](=O)[O-].ClC1=C(C(=NC=C1Cl)N)[N+](=O)[O-] HEBUHZMNOXZMEU-UHFFFAOYSA-N 0.000 description 1
- LYWNYZSURYYZRD-UHFFFAOYSA-N ClC=1C(=C(C(=NC=1)N)[N+](=O)[O-])NC1CCN(CC1)CC=1C(=NN(C=1C)C)C Chemical compound ClC=1C(=C(C(=NC=1)N)[N+](=O)[O-])NC1CCN(CC1)CC=1C(=NN(C=1C)C)C LYWNYZSURYYZRD-UHFFFAOYSA-N 0.000 description 1
- UOOPOMDCFNSQFW-UHFFFAOYSA-N ClC=1C(=C(C(=NC=1)N)[N+](=O)[O-])NC1CCN(CC1)CC=1SC=CC=1 Chemical compound ClC=1C(=C(C(=NC=1)N)[N+](=O)[O-])NC1CCN(CC1)CC=1SC=CC=1 UOOPOMDCFNSQFW-UHFFFAOYSA-N 0.000 description 1
- WJZUEEYDJNGEGN-LURJTMIESA-N ClC=1C(=C(C(=NC=1)N)[N+](=O)[O-])N[C@@H]1CN(CC1)C Chemical compound ClC=1C(=C(C(=NC=1)N)[N+](=O)[O-])N[C@@H]1CN(CC1)C WJZUEEYDJNGEGN-LURJTMIESA-N 0.000 description 1
- AKWQQDIAXNDYFY-QMMMGPOBSA-N ClC=1C(=C(C(=NC=1)N)[N+](=O)[O-])N[C@@H]1CN(CC1)CCC Chemical compound ClC=1C(=C(C(=NC=1)N)[N+](=O)[O-])N[C@@H]1CN(CC1)CCC AKWQQDIAXNDYFY-QMMMGPOBSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 208000010007 Cogan syndrome Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010252 Concentric sclerosis Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- 208000024134 Diffuse cutaneous systemic sclerosis Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 208000004332 Evans syndrome Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- XTGIYIDTODXVLN-UHFFFAOYSA-N FC(C(=O)O)(F)F.COCC(=O)N1CCNCC1 Chemical compound FC(C(=O)O)(F)F.COCC(=O)N1CCNCC1 XTGIYIDTODXVLN-UHFFFAOYSA-N 0.000 description 1
- DRIBDPFWIPCHDZ-UHFFFAOYSA-N FC(C(=O)O)(F)F.COCCC(=O)N1CCNCC1 Chemical compound FC(C(=O)O)(F)F.COCCC(=O)N1CCNCC1 DRIBDPFWIPCHDZ-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 208000016905 Hashimoto encephalopathy Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010062639 Herpes dermatitis Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 208000027601 Inner ear disease Diseases 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 206010062038 Lip neoplasm Diseases 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- LYOOJMYHJNUNBT-UHFFFAOYSA-N N-(2-chloroethyl)-2-methylpyrazol-3-amine Chemical compound ClCCNC1=CC=NN1C LYOOJMYHJNUNBT-UHFFFAOYSA-N 0.000 description 1
- DLGAQEYVNNYFQF-UHFFFAOYSA-N N-(4,5-dichloropyridin-2-yl)nitramide Chemical compound ClC1=CC(=NC=C1Cl)N[N+](=O)[O-] DLGAQEYVNNYFQF-UHFFFAOYSA-N 0.000 description 1
- ZGMCGBHMQXTFHU-UHFFFAOYSA-N N-(5-bromo-4-chloropyridin-2-yl)nitramide Chemical compound BrC=1C(=CC(=NC=1)N[N+](=O)[O-])Cl ZGMCGBHMQXTFHU-UHFFFAOYSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Substances BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000010505 Nose Neoplasms Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 208000025174 PANDAS Diseases 0.000 description 1
- 206010053869 POEMS syndrome Diseases 0.000 description 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 208000000766 Pityriasis Lichenoides Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 201000008183 Pulmonary blastoma Diseases 0.000 description 1
- 108091008554 ROR receptors Proteins 0.000 description 1
- 206010071141 Rasmussen encephalitis Diseases 0.000 description 1
- 208000004160 Rasmussen subacute encephalitis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010070308 Refractory cancer Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 201000010848 Schnitzler Syndrome Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000032384 Severe immune-mediated enteropathy Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000010265 Sweet syndrome Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000025851 Undifferentiated connective tissue disease Diseases 0.000 description 1
- 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 208000002223 abdominal aortic aneurysm Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 208000007474 aortic aneurysm Diseases 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 201000004984 autoimmune cardiomyopathy Diseases 0.000 description 1
- 208000001974 autoimmune enteropathy Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000004339 autoimmune neuropathy Diseases 0.000 description 1
- 201000005011 autoimmune peripheral neuropathy Diseases 0.000 description 1
- 201000011385 autoimmune polyendocrine syndrome Diseases 0.000 description 1
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 description 1
- 206010071572 autoimmune progesterone dermatitis Diseases 0.000 description 1
- 208000029407 autoimmune urticaria Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000000069 breast epithelial cell Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 201000004559 cerebral degeneration Diseases 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 201000003056 complement component 2 deficiency Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical class C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000004981 cycloalkylmethyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- JMYVMOUINOAAPA-UHFFFAOYSA-N cyclopropanecarbaldehyde Chemical compound O=CC1CC1 JMYVMOUINOAAPA-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- YYRGUTODIPXGGS-UHFFFAOYSA-N diazepan-5-one Chemical compound O=C1CCNNCC1 YYRGUTODIPXGGS-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 201000004997 drug-induced lupus erythematosus Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- CKSJXOVLXUMMFF-UHFFFAOYSA-N exalamide Chemical compound CCCCCCOC1=CC=CC=C1C(N)=O CKSJXOVLXUMMFF-UHFFFAOYSA-N 0.000 description 1
- 229950010333 exalamide Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
- 208000002980 facial hemiatrophy Diseases 0.000 description 1
- 206010016165 failure to thrive Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- CNUDBTRUORMMPA-UHFFFAOYSA-N formylthiophene Chemical compound O=CC1=CC=CS1 CNUDBTRUORMMPA-UHFFFAOYSA-N 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 150000002238 fumaric acids Chemical class 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 125000005611 glucoheptonic acid group Chemical group 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000049583 human ROR1 Human genes 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- KRGRHIQRVYJCIG-UHFFFAOYSA-N hydron;1-propan-2-ylpiperidin-4-amine;dichloride Chemical compound Cl.Cl.CC(C)N1CCC(N)CC1 KRGRHIQRVYJCIG-UHFFFAOYSA-N 0.000 description 1
- MSQACBWWAIBWIC-UHFFFAOYSA-N hydron;piperazine;chloride Chemical compound Cl.C1CNCCN1 MSQACBWWAIBWIC-UHFFFAOYSA-N 0.000 description 1
- BNTRVUUJBGBGLZ-UHFFFAOYSA-N hydron;pyridine-4-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=NC=C1 BNTRVUUJBGBGLZ-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 150000005232 imidazopyridines Chemical class 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 208000014899 intrahepatic bile duct cancer Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000002741 leukoplakia Diseases 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002689 maleic acids Chemical class 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 150000002691 malonic acids Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- XOPUORAQCYGJPT-UHFFFAOYSA-N methanesulfonic acid;hydrochloride Chemical compound Cl.CS(O)(=O)=O XOPUORAQCYGJPT-UHFFFAOYSA-N 0.000 description 1
- DGEYTDCFMQMLTH-UHFFFAOYSA-N methanol;propan-2-ol Chemical compound OC.CC(C)O DGEYTDCFMQMLTH-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 206010063344 microscopic polyangiitis Diseases 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 208000037830 nasal cancer Diseases 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 201000011682 nervous system cancer Diseases 0.000 description 1
- 210000001020 neural plate Anatomy 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 208000008795 neuromyelitis optica Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 125000005489 p-toluenesulfonic acid group Chemical class 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- VYSFCBZMPSKWOF-UHFFFAOYSA-N piperazin-1-yl(pyridin-3-yl)methanone Chemical compound C=1C=CN=CC=1C(=O)N1CCNCC1 VYSFCBZMPSKWOF-UHFFFAOYSA-N 0.000 description 1
- SGQDWDWJCYEUNC-UHFFFAOYSA-N piperidin-1-ium-4-ylazanium;dichloride Chemical compound Cl.Cl.NC1CCNCC1 SGQDWDWJCYEUNC-UHFFFAOYSA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 1
- 201000002511 pituitary cancer Diseases 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical class CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 208000010626 plasma cell neoplasm Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 150000004672 propanoic acids Chemical class 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- ATBIAJXSKNPHEI-UHFFFAOYSA-N pyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1 ATBIAJXSKNPHEI-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- FREJAOSUHFGDBW-UHFFFAOYSA-N pyrimidine-5-carbaldehyde Chemical compound O=CC1=CN=CN=C1 FREJAOSUHFGDBW-UHFFFAOYSA-N 0.000 description 1
- SBMSLRMNBSMKQC-UHFFFAOYSA-N pyrrolidin-1-amine Chemical compound NN1CCCC1 SBMSLRMNBSMKQC-UHFFFAOYSA-N 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- JZWFDVDETGFGFC-UHFFFAOYSA-N salacetamide Chemical group CC(=O)NC(=O)C1=CC=CC=C1O JZWFDVDETGFGFC-UHFFFAOYSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 206010039722 scoliosis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000037968 sinus cancer Diseases 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 150000003444 succinic acids Chemical class 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- WDPWEXWMQDRXAL-UHFFFAOYSA-N tert-butyl 1,4-diazepane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCNCC1 WDPWEXWMQDRXAL-UHFFFAOYSA-N 0.000 description 1
- QGYZPKJTYSQFDY-UHFFFAOYSA-N tert-butyl 3-oxo-4-(2-propan-2-yloxyethyl)piperazine-1-carboxylate Chemical compound CC(C)OCCN1C(CN(CC1)C(=O)OC(C)(C)C)=O QGYZPKJTYSQFDY-UHFFFAOYSA-N 0.000 description 1
- FCMLWBBLOASUSO-UHFFFAOYSA-N tert-butyl 3-oxopiperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNC(=O)C1 FCMLWBBLOASUSO-UHFFFAOYSA-N 0.000 description 1
- KBBFHRDZKMRNAH-UHFFFAOYSA-N tert-butyl 4-(2,2-dimethylpropanoyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(C(=O)C(C)(C)C)CC1 KBBFHRDZKMRNAH-UHFFFAOYSA-N 0.000 description 1
- FYGFAIVVCQSWQG-UHFFFAOYSA-N tert-butyl 4-(2-ethoxyethyl)-1,4-diazepane-1-carboxylate Chemical compound CCOCCN1CCCN(C(=O)OC(C)(C)C)CC1 FYGFAIVVCQSWQG-UHFFFAOYSA-N 0.000 description 1
- GMZZQHJIPGFKDM-UHFFFAOYSA-N tert-butyl 4-(2-ethoxyethyl)-3-oxopiperazine-1-carboxylate Chemical compound C(C)OCCN1C(CN(CC1)C(=O)OC(C)(C)C)=O GMZZQHJIPGFKDM-UHFFFAOYSA-N 0.000 description 1
- HLZUKYQPNUWHCT-UHFFFAOYSA-N tert-butyl 4-(2-ethoxyethyl)piperidine-1-carboxylate Chemical compound CCOCCC1CCN(C(=O)OC(C)(C)C)CC1 HLZUKYQPNUWHCT-UHFFFAOYSA-N 0.000 description 1
- BYULDJDQOOPAAB-UHFFFAOYSA-N tert-butyl 4-(2-methoxyacetyl)piperazine-1-carboxylate Chemical compound COCC(=O)N1CCN(C(=O)OC(C)(C)C)CC1 BYULDJDQOOPAAB-UHFFFAOYSA-N 0.000 description 1
- POZSWKMHQIXGBR-UHFFFAOYSA-N tert-butyl 4-(2-methoxyethyl)-1,4-diazepane-1-carboxylate Chemical compound COCCN1CCCN(C(=O)OC(C)(C)C)CC1 POZSWKMHQIXGBR-UHFFFAOYSA-N 0.000 description 1
- DBIUTFHJLAJTFB-UHFFFAOYSA-N tert-butyl 4-(2-methoxyethyl)-2-methylpiperazine-1-carboxylate Chemical compound COCCN1CC(N(CC1)C(=O)OC(C)(C)C)C DBIUTFHJLAJTFB-UHFFFAOYSA-N 0.000 description 1
- LGXQQIMQVKUOCA-UHFFFAOYSA-N tert-butyl 4-(2-methoxyethyl)-3-methylpiperazine-1-carboxylate Chemical compound COCCN1CCN(C(=O)OC(C)(C)C)CC1C LGXQQIMQVKUOCA-UHFFFAOYSA-N 0.000 description 1
- DYHAFQGLDMSQCD-UHFFFAOYSA-N tert-butyl 4-(2-methoxyethyl)-3-oxopiperazine-1-carboxylate Chemical compound COCCN1CCN(C(=O)OC(C)(C)C)CC1=O DYHAFQGLDMSQCD-UHFFFAOYSA-N 0.000 description 1
- MQFWLBMPVPCNRM-UHFFFAOYSA-N tert-butyl 4-(2-methoxyethyl)piperidine-1-carboxylate Chemical compound COCCC1CCN(C(=O)OC(C)(C)C)CC1 MQFWLBMPVPCNRM-UHFFFAOYSA-N 0.000 description 1
- ZEWKCJCJAJKVJS-UHFFFAOYSA-N tert-butyl 4-(2-propan-2-yloxyethyl)-1,4-diazepane-1-carboxylate Chemical compound CC(C)OCCN1CCN(CCC1)C(=O)OC(C)(C)C ZEWKCJCJAJKVJS-UHFFFAOYSA-N 0.000 description 1
- PSHJJSORIUOEEA-UHFFFAOYSA-N tert-butyl 4-(3-methoxypropanoyl)piperazine-1-carboxylate Chemical compound COCCC(=O)N1CCN(CC1)C(=O)OC(C)(C)C PSHJJSORIUOEEA-UHFFFAOYSA-N 0.000 description 1
- SEHZHKYVLKVITL-UHFFFAOYSA-N tert-butyl 4-(3-methoxypropyl)-2-methylpiperazine-1-carboxylate Chemical compound COCCCN1CC(N(CC1)C(=O)OC(C)(C)C)C SEHZHKYVLKVITL-UHFFFAOYSA-N 0.000 description 1
- MZYKPADENGYIBG-UHFFFAOYSA-N tert-butyl 4-(3-methoxypropyl)-3-methylpiperazine-1-carboxylate Chemical compound COCCCN1CCN(C(=O)OC(C)(C)C)CC1C MZYKPADENGYIBG-UHFFFAOYSA-N 0.000 description 1
- PVOXCLUZLLXFLM-UHFFFAOYSA-N tert-butyl 4-(3-methoxypropyl)-3-oxopiperazine-1-carboxylate Chemical compound COCCCN1CCN(C(=O)OC(C)(C)C)CC1=O PVOXCLUZLLXFLM-UHFFFAOYSA-N 0.000 description 1
- CEXGIKWOQJMOKU-UHFFFAOYSA-N tert-butyl 4-[2-(2-methoxyethoxy)ethyl]piperazine-1-carboxylate Chemical compound COCCOCCN1CCN(C(=O)OC(C)(C)C)CC1 CEXGIKWOQJMOKU-UHFFFAOYSA-N 0.000 description 1
- OTBBDCMPKZSOMD-UHFFFAOYSA-N tert-butyl 4-benzyl-3-oxopiperazine-1-carboxylate Chemical compound O=C1CN(C(=O)OC(C)(C)C)CCN1CC1=CC=CC=C1 OTBBDCMPKZSOMD-UHFFFAOYSA-N 0.000 description 1
- GVHSMUYEAWMYLM-UHFFFAOYSA-N tert-butyl 4-benzylpiperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CC1=CC=CC=C1 GVHSMUYEAWMYLM-UHFFFAOYSA-N 0.000 description 1
- SLWXQUHGEUNYSN-UHFFFAOYSA-N tert-butyl 4-methyl-3-oxopiperazine-1-carboxylate Chemical compound CN1CCN(C(=O)OC(C)(C)C)CC1=O SLWXQUHGEUNYSN-UHFFFAOYSA-N 0.000 description 1
- JUOXFFYHDMNFHE-UHFFFAOYSA-N tert-butyl n-(1-ethylpiperidin-4-yl)carbamate Chemical compound CCN1CCC(NC(=O)OC(C)(C)C)CC1 JUOXFFYHDMNFHE-UHFFFAOYSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000009174 transverse myelitis Diseases 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 210000000239 visual pathway Anatomy 0.000 description 1
- 230000004400 visual pathway Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16178928.4 | 2016-07-11 | ||
| EP16178928 | 2016-07-11 | ||
| PCT/EP2017/067262 WO2018011138A1 (en) | 2016-07-11 | 2017-07-10 | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019520412A JP2019520412A (ja) | 2019-07-18 |
| JP2019520412A5 JP2019520412A5 (enExample) | 2020-07-27 |
| JP6891262B2 true JP6891262B2 (ja) | 2021-06-18 |
Family
ID=56409027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019500778A Expired - Fee Related JP6891262B2 (ja) | 2016-07-11 | 2017-07-10 | 哺乳動物のチロシンキナーゼｒｏｒ１活性の阻害剤として有用な２−フェニルイミダゾ［４，５−ｂ］ピリジン−７−アミン誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11008318B2 (enExample) |
| EP (1) | EP3481824B1 (enExample) |
| JP (1) | JP6891262B2 (enExample) |
| KR (1) | KR102466810B1 (enExample) |
| CN (1) | CN109563092B (enExample) |
| ES (1) | ES2899113T3 (enExample) |
| WO (1) | WO2018011138A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201710838D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
| GB201710835D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
| GB201710836D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
| JP7301862B2 (ja) * | 2018-02-23 | 2023-07-03 | フラウンホーファー－ゲゼルシャフト ツル フェルデルング デル アンゲヴァンテン フォルシュング エー ファウ | 歯周病及び関連疾患の治療に用いる細菌性グルタミニルシクラーゼの新規阻害剤 |
| WO2021057696A1 (zh) * | 2019-09-27 | 2021-04-01 | 隆泰申医药科技(南京)有限公司 | 一种杂芳基类化合物及其应用 |
| WO2022057849A1 (zh) * | 2020-09-17 | 2022-03-24 | 浙江海正药业股份有限公司 | 哌嗪类衍生物及其制备方法和用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003045929A1 (en) | 2001-11-26 | 2003-06-05 | Takeda Chemical Industries, Ltd. | Bicyclic derivative, process for producing the same, and use |
| SE0202464D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Use of compounds |
| SE0202462D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel use |
| EP1833829A2 (en) | 2004-12-23 | 2007-09-19 | F. Hoffmann-Roche AG | Benzamide substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors |
| CA2589877A1 (en) | 2004-12-23 | 2006-06-29 | F. Hoffmann-La Roche Ag | Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors |
| EP1861387B1 (en) | 2005-01-28 | 2014-04-16 | Daewoong Pharmaceutical Co., Ltd. | Benzimidazole derivatives and pharmaceutical compositions thereof |
| EP1891069A1 (en) | 2005-05-24 | 2008-02-27 | AstraZeneca AB | 2-phenyl substituted imidazol [4,5b]pyridine/ pyrazine and purine derivatives as glucokinase modulators |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| EP1963315B1 (en) | 2005-12-22 | 2014-10-08 | Cancer Research Technology Limited | Enzyme inhibitors |
| JP2009523845A (ja) | 2006-01-23 | 2009-06-25 | クリスタルゲノミクス インコーポレーテッド | たんぱく質キナーゼの活性を阻害するイミダゾピリジン誘導体、これの製造方法およびこれを含む薬学組成物 |
| WO2008121064A1 (en) | 2007-03-30 | 2008-10-09 | Astrazeneca Ab | New imidazo[4,5-b]pyridine-6-halo-7-aryl/heteroaryl compounds 705 |
| JP2010523490A (ja) | 2007-03-30 | 2010-07-15 | アストラゼネカ・アクチエボラーグ | 新規イミダゾ［４，５−ｂ］ピリジン−７−カルボキサミド７０４ |
| WO2009001021A1 (en) | 2007-06-26 | 2008-12-31 | Chroma Therapeutics Ltd. | Imidazopyridine derivatives useful as enzyme inhibitors for the treatment of cell proliferative and autoimmune diseases |
| CA2716947A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Imidazo [4,5-b] pyridine derivatives used as raf inhibitors |
| JP2013512245A (ja) | 2009-11-24 | 2013-04-11 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 脂肪酸合成酵素阻害剤としてのアザベンズイミダゾール |
| US9150647B2 (en) | 2009-12-18 | 2015-10-06 | Kancera Ab | Biological inhibitors of ROR1 capable of inducing cell death |
| KR20130076046A (ko) * | 2011-12-28 | 2013-07-08 | 한미약품 주식회사 | 타이로신 카이네이즈 억제 활성을 갖는 신규 이미다조피리딘 유도체 |
| ES2567552T3 (es) * | 2012-01-30 | 2016-04-25 | Cephalon, Inc. | Imidazo [4,5-b] derivados de piridina como los moduladores ALK y JAK para el tratamiento de trastornos proliferativos |
| US9925193B2 (en) * | 2012-11-20 | 2018-03-27 | Proqinase Gmbh | Thioether derivatives as protein kinase inhibitors |
| EP3253754B1 (en) * | 2015-02-02 | 2021-03-31 | Kancera AB | 2-phenyl-3h-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity |
-
2017
- 2017-07-10 US US16/314,708 patent/US11008318B2/en not_active Expired - Fee Related
- 2017-07-10 EP EP17735582.3A patent/EP3481824B1/en not_active Not-in-force
- 2017-07-10 CN CN201780043024.7A patent/CN109563092B/zh not_active Expired - Fee Related
- 2017-07-10 ES ES17735582T patent/ES2899113T3/es active Active
- 2017-07-10 JP JP2019500778A patent/JP6891262B2/ja not_active Expired - Fee Related
- 2017-07-10 WO PCT/EP2017/067262 patent/WO2018011138A1/en not_active Ceased
- 2017-07-10 KR KR1020197003657A patent/KR102466810B1/ko active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200024272A1 (en) | 2020-01-23 |
| EP3481824A1 (en) | 2019-05-15 |
| EP3481824B1 (en) | 2021-10-20 |
| JP2019520412A (ja) | 2019-07-18 |
| CN109563092B (zh) | 2021-09-14 |
| KR102466810B1 (ko) | 2022-11-11 |
| WO2018011138A1 (en) | 2018-01-18 |
| CN109563092A (zh) | 2019-04-02 |
| ES2899113T3 (es) | 2022-03-10 |
| US11008318B2 (en) | 2021-05-18 |
| KR20190026006A (ko) | 2019-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2702906C2 (ru) | Птеридины в качестве fgfr ингибиторов | |
| KR101889565B1 (ko) | 피라졸릴 퀴녹살린 키나제 억제제 | |
| JP2023513854A (ja) | 大環状化合物およびその使用 | |
| RU2701517C2 (ru) | Производные хиназолинона, применимые в качестве модуляторов fgfr киназы | |
| RU2629194C2 (ru) | Производные 1,5- и 1,7-нафтиридина, полезные при лечении заболеваний, опосредованных fgfr | |
| CN109867676B (zh) | 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途 | |
| TWI534145B (zh) | 四氫吡啶并嘧啶衍生物 | |
| AU2014231437B2 (en) | Novel pyrimidine and pyridine compounds and their usage | |
| KR102466810B1 (ko) | 포유류 티로신 키나제 ror1 활성의 저해제로서 유용한 2-페닐이미다조[4,5-b]피리딘-7-아민 유도체 | |
| JP5937111B2 (ja) | Ｆａｋ阻害剤 | |
| JP6629884B2 (ja) | 哺乳動物のチロシンキナーゼｒｏｒ１活性の阻害剤として有用な２−フェニル−３ｈ−イミダゾ［４，５−ｂ］ピリジン誘導体 | |
| CN107074812B (zh) | 取代的嘧啶化合物 | |
| EA020807B1 (ru) | Соединения пиридина | |
| JP7625141B2 (ja) | Ｅｒｂｂ２の阻害剤としての縮合四環キナゾリン誘導体 | |
| JPWO2016208592A1 (ja) | 二環性複素環アミド誘導体 | |
| CN117203199A (zh) | N2-苯基嘧啶-2,4-二胺化合物及其制备方法和使用方法 | |
| JP2024505732A (ja) | ピリドピリミジノン系誘導体及びその製造方法と使用 | |
| JP2019519512A (ja) | ピリミジン誘導体、その調製方法および医療での使用 | |
| JP2015524826A (ja) | Ｖｅｇｆｒ３阻害剤 | |
| CN111909133B (zh) | 作为布鲁诺酪氨酸激酶抑制剂的取代的1-氨基-1h-咪唑-5-甲酰胺 | |
| CN120590414A (zh) | 一类含氮杂环类化合物、制备方法和用途 | |
| JP2022512358A (ja) | キノリン構造を有するｐａｎ－ＫＩＴキナーゼ阻害剤及びその適用 | |
| CN120058702A (zh) | 含杂环的tead抑制剂 | |
| US11660303B2 (en) | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity | |
| HK40032523B (en) | Substituted 1-amino-1h-imidazole-5-carboxamides as brunauer tyrosine kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200615 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200615 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210426 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210428 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210526 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6891262 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |